Composition for promoting hair growth

Oral estetrol administration addresses the limitations of current estrogen therapies by targeting hair follicle compartments to enhance hair growth and prevent loss, achieving improved hair texture and density without systemic side effects.

JP2024543177APending Publication Date: 2024-11-19ESTETRA SRL
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024531585
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-29
Filing Date
2022-11-29
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Current estrogen-related therapies for hair loss and hair growth, such as topical application of estrogens like estradiol, face challenges in effectively targeting hair follicle regeneration and are associated with systemic side effects, necessitating the development of new compositions that avoid these issues.

Method used

Oral administration of estetrol in specific dosage ranges targets hair follicle mesenchymal and epithelial compartments, promoting epithelial-mesenchymal interactions, increasing keratinocyte and fibroblast proliferation, and enhancing sebum secretion to prevent or reverse hair loss and promote hair growth.

Benefits of technology

Estetrol effectively reaches the skin after oral administration, improving hair texture, quality, and appearance by prolonging the anagen phase, reducing hair loss, and increasing hair count and width, without significant systemic side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543177000013
    Figure 2024543177000013
  • Figure 2024543177000014
    Figure 2024543177000014
  • Figure 2024543177000015
    Figure 2024543177000015
Patent Text Reader

Abstract

The present invention relates to compositions for preventing hair loss and / or promoting hair growth, to cosmetic or therapeutic treatments in which such compositions are used, and to related formulations or dosage units containing such compositions.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to compositions for the prevention of hair loss and / or the promotion of hair growth, to cosmetic or therapeutic treatments in which such compositions are used, and to related formulations or dosage units containing such compositions.

[0002] As described in more detail herein, this treatment demonstrates statistically significant efficacy coupled with a favorable side effect profile when compared to currently available methods for preventing hair loss or promoting hair growth. [Background technology]

[0003] With age, the rate of hair growth decreases with a reduction in hair thickness. Gray hair appears as a result of decreased melanin production in the hair matrix. This effect is exacerbated in menopausal women (i.e., peri- and post-menopausal women) due to the influence of hormonal imbalance, often leading to a negative self-image. Changes in hormone balance can affect the composition of the skin and the function of hair follicles. The secretion of the sebaceous glands (sebum) also provides an emollient for the hair and skin and is under the influence of androgenic hormones. Sebum secretion decreases with age and can also be affected by estrogen levels.

[0004] The hair follicle cycle is characterized by a period of growth of the hair follicle (anagen), followed by a period of regression and remodeling (catagen), and finally a period of rest (telogen).

[0005] Estrogen levels have been linked to both hair growth and hair loss. For example, during pregnancy, women's estrogen levels are higher than normal, which increases hair follicle growth, leading to fuller, fuller hair. In contrast, when estrogen levels drop, such as after pregnancy or during and after menopause, more hair follicles enter a "resting" period, which leads to hair loss, reduced hair volume, and even partial baldness.

[0006] Topical application of compositions containing estrogens, such as estradiol (E2) or estetrol (E4), to the skin has been widely studied. See, for example, US Pat. No. 5,399,633, which reports on the topical application of cosmetic compositions containing estetrol. Therein, some effects of applying estrogen to the skin were suggested to include slowing the rate of hair growth, which was considered beneficial for avoiding facial hair growth in menopausal women, etc.

[0007] In the literature, local application of estrogen is considered favorable, as reported, for example, by Hye-Sun Oh and Robert C. Smart (Non-Patent Document 1), and the literature generally states that it is difficult to distinguish between the effects of local and systemic factors that regulate hair follicle cycles.In summary, the results show that the hair growth regulating effects of locally applied E2 and ICI-182780 (a pure estrogen receptor antagonist) occur locally rather than systemically.

[0008] Oral (systemic) administration of hormone replacement therapy including estrogen is usually not considered the best option for cosmetic applications, for example, for hair loss / growth, but it is an interesting route because it avoids the need to apply creams etc. to the skin / scalp every day, which can be a bothersome and / or unpleasant experience for some subjects. Another advantage is that the symptoms associated with menopause can be simultaneously alleviated by systemic use of estrogen at a certain dose. However, one long-standing concern with this form of administration is the need to avoid side effects associated with such systemic administration or accumulation of estrogen in the subject. For example, Patent Document 1 describes that topical application of estrogen is preferred for treating the skin. Conversely, this document describes that menopausal symptoms should be treated separately by oral or subcutaneous administration. Also, the proposed dosage was too low to suppress symptoms of hypoestrogenism.

[0009] However, there remains a need to develop new compositions or formulations that overcome some of these identified problems without increasing the risk of adverse effects such as those associated with current estrogen-related therapies. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] PCT Application International Publication No. 03 / 103685 [Non-patent literature]

[0011] [Non-Patent Document 1] PNAS, Vol. 93, pp. 12525-12530, October 1996 Summary of the Invention

[0012] The ability of the hair follicle (HF) to constantly self-renew and undergo repeated cycles depends on the interactions that occur between its mesenchymal and epithelial compartments, the so-called epithelial-mesenchymal interactions (EMI). Therefore, effective strategies aimed at promoting HF regeneration / stimulation will be most successful when targeting not only the combination of relevant cell populations but also their function / signaling and / or migration. The HF mesenchyme mainly contains specialized dermal papilla (DP) cells, while the epithelial part usually contains keratinocytes (KCs) that can be present in different hair follicle sources including the bulge, the outer root sheath (ORS) or the hair bulb itself. Such epithelial cells can be derived from epidermal KCs with stem-like characteristics, which belong to the hair follicle itself or are present in the skin and can form the HF epithelium, form EMI with DP cells, support the growth of DP cells and promote the formation of HF and sebaceous gland-like structures (Abreu et al., 2021, Stem Cell Research & Therapy volume 12, Article number: 62).

[0013] In postnatal life, hair follicles undergo cyclical growth including resting periods (telogen), growth periods (anagen) and regression periods (catagen). During catagen, epithelial (keratinocyte) cells at the base of the follicle undergo apoptosis, while DP cells (fibroblasts) remain intact and are pulled or migrate upwards until they come to rest adjacent to stem cells in the follicle bulge. This state continues with a telogen (resting) period. In anagen, cells at the base of the follicle begin to proliferate, which leads to the downgrowth of the follicle and the envelopment of the DP. DP cells themselves are not thought to divide (virtually), but the number of cells in the DP increases during anagen, possibly due to recruitment from adjacent cells in the dermal sheath (mesenchymal cells - fibroblasts). At the onset of anagen (growth), the DP activates the stem cells of the secondary hair germ, which leads to a new downgrowth of the follicle. During catagen (involution), the hair follicle becomes separated from its blood supply and the hair follicle cells undergo apoptosis.

[0014] Against this background, the inventors have now surprisingly found that oral administration of estetrol in a certain dosage range can be advantageous for preventing or reversing hair loss associated with or caused by menopausal hormone imbalance, and for increasing hair growth in menopausal (peri- or post-menopausal) women.This leads to improving hair texture, hair quality and hair appearance.More specifically, this leads to improving certain parameters, such as (but not limited to) target area hair count ("TAHC") and target area hair width ("TAHW").

[0015] Unexpectedly, it has been shown that clinically relevant concentrations of E4 reach the skin after oral administration. Moreover, unlike E2, E4 can act on all epidermal keratinocytes, including, for example, bulge, outer root sheath (ORS) or hair bulb cells, dermal fibroblasts, for example, dermal papilla (DP) cells, and sebaceous glands. Estetrol has been shown to have several beneficial effects on preventing or reducing hair loss, ranging from influencing fibroblast and keratinocyte proliferation, migration, and epithelial-mesenchymal interactions, to activating hair follicles and increasing sebum secretion. Furthermore, estetrol has been shown to have effects such as reducing skin inflammation, which leads to hair follicle health. This opens up the opportunity to provide oral formulations or dosage units that can be used to prevent or reduce hair loss.

[0016] Without wishing to be bound by any theory, it is believed that estetrol (unlike estradiol, for example) can promote and / or prolong the anagen phase and thus the growth of hair follicles by acting on keratinocytes, and / or delay the onset of catagen by increasing the proliferation and / or reducing the apoptosis of keratinocytes, thereby reducing hair loss.In addition, it is believed that estetrol improves epithelial-mesenchymal interaction by acting on fibroblasts (i.e. including DP cells), which leads to the activation of DP cells and hair growth.

[0017] In the following numbered paragraphs, some specific embodiments of the present invention are described.

[0018] Aspect 1. An oral dosage unit comprising an estetrol component in an amount equivalent to about 10 mg to about 25 mg of estetrol, preferably in a daily amount equivalent to about 10 mg to about 25 mg of estetrol, for use in the prevention or treatment of hair loss.

[0019] Aspect 2. Use of an effective amount of an estetrol component in the manufacture of a composition or medicament for the prevention or treatment of hair loss, wherein the estetrol component is used in a daily amount equivalent to about 10 mg to about 25 mg of estetrol.

[0020] Aspect 3. A method for preventing or treating hair loss comprising oral administration (or oral ingestion) of an estetrol component in a daily amount equivalent to about 10 mg to about 25 mg of estetrol.

[0021] Aspect 4. A cosmetic method for preventing or treating hair loss comprising oral administration (or oral ingestion) of an estetrol component in a daily amount equivalent to about 10 mg to about 25 mg of estetrol, preferably comprising oral administration of a composition comprising about 10 mg to about 25 mg of the estetrol component.

[0022] Aspect 5. An oral dosage unit for use according to aspect 1, a use according to aspect 2, a method for prevention or treatment according to aspect 3 or a method according to aspect 4, wherein said prevention or treatment comprises or results in an improvement in hair texture, quality and appearance, preferably wherein said prevention or treatment comprises or results in an improvement in Target Area Hair Count (TAHC) and / or Target Area Hair Width (TAHW).

[0023] Aspect 6. An oral dosage unit for use, use or method according to any one of aspects 1 to 5, wherein said hair loss is hormone-related hair loss, more preferably hair loss caused by menopausal hormone deregulation such as estrogen deficiency.

[0024] Aspect 7. An oral dosage unit for use, use or method according to any one of aspects 1 to 6, wherein the hair loss is caused by hair disorders in postmenopausal women.

[0025] Aspect 8. An oral dosage unit for use, use or method according to any one of aspects 1 to 7, wherein said hair loss is female pattern hair loss or female androgenetic alopecia (AGA) (i.e. female pattern hair loss).

[0026] Aspect 9. An oral dosage unit for use, use or method according to any one of aspects 1 to 8, wherein said prevention or treatment comprises preventing hair loss, reversing hair loss, slowing down the rate of hair loss, reducing hair loss, increasing hair growth or leads to an improvement in the texture, quality and / or appearance of hair.

[0027] Aspect 10. An oral dosage unit for use, use or method according to any one of aspects 1 to 9, wherein said prevention or treatment increases the function and / or growth of keratinocytes, and in this regard, preferably increases the function and / or growth of epidermal keratinocytes (KC), such as those belonging to the bulge, outer root sheath (ORS) or hair bulb.

[0028] Aspect 11. An oral dosage unit for use, use or method according to any one of aspects 1 to 10, wherein said prevention or treatment increases the function and / or growth of hair follicle mesenchymal fibroblasts and, in this regard, increases the function and / or growth of dermal papilla (DP) cells (i.e. a form of fibroblast specialized for the induction of differentiated hair).

[0029] Aspect 12. An oral dosage unit for use, use or method according to any one of Aspects 1 to 11, wherein said prevention or treatment means delaying the onset of regression phase or preventing regression phase.

[0030] Aspect 13. An oral dosage unit for use, use or method according to any one of aspects 1 to 12, wherein said prevention or treatment refers to the promotion and / or prolongation of anagen.

[0031] Aspect 14. An oral dosage unit for use, use or method according to any one of aspects 1 to 13, wherein said prevention or treatment refers to the restoration and / or promotion of epithelial-mesenchymal interaction between hair follicle cells.

[0032] Aspect 15. An oral dosage unit for use, use or method according to any one of aspects 1 to 14, wherein said prevention or treatment is characterized by a reduction in inflammation and / or oxidative stress in hair follicles.

[0033] Aspect 16. An oral dosage unit for use, use, or method according to any one of aspects 1 to 15, wherein a daily amount equivalent to about 14 mg to about 21 mg of estetrol, preferably about 14 mg to about 16 mg or about 19 mg to about 21 mg of estetrol, is administered.

[0034] Aspect 17. An oral dosage unit for use, use, or method according to any one of aspects 1 to 16, wherein the estetrol component is estetrol or an ester thereof.

[0035] Aspect 18. An oral dosage unit for use, use, or method according to any one of aspects 1 to 17, wherein the estetrol component is estetrol monohydrate.

[0036] Aspect 19. An oral dosage unit for use, a use, or a method according to any one of aspects 1 to 18, wherein said dosage unit does not contain a progestogen, or wherein no progestogen is used or is not co-administered.

[0037] Aspect 20. An oral dosage unit for use, a use or a method according to any one of aspects 1 to 19, wherein a progestogen is present in the oral dosage unit or a progestogen is used, co-administered or administered after treatment with estetrol.

[0038] Aspect 21. The oral dosage unit for use, use or method according to aspect 20, wherein said progestogen is selected from the group comprising progesterone, drospirenone, norethisterone, norethisterone-acetate (NETA), norethindrone, dydrogesterone, levonorgestrel (LNG), etonogestrel, norgestrel, nomegestrol, nomegestrol-acetate (NOMAC), trimegestone, nestorone, dydrogesterone, gestodene, desogestrel, norgestimate, cyproterone acetate, dienogest and chlormadinone. In a preferred embodiment, said progestogen is selected from the group comprising drospirenone, progesterone or dydrogesterone.

[0039] Aspect 22. An oral dosage unit, use or method for use according to aspect 20 or 21, wherein the progestogen is present in the oral dosage unit in an amount equivalent to about 0.25 mg to about 4 mg, such as about 1 mg to about 4 mg, more preferably about 1 mg to about 3 mg, such as about 2.5 mg to 3.5 mg of drospirenone, or the progestogen is administered in an amount equivalent to about 2.5 mg to 3.5 mg of drospirenone. In a preferred embodiment, the progestogen is drospirenone.

[0040] Aspect 23. An oral dosage unit, use or method for use according to aspect 20 or 21, wherein said progestogen is present in said oral dosage unit in an amount equivalent to about 1 mg to 20 mg of progesterone, or said progestogen is administered in an amount equivalent to about 5 mg to 10 mg of progesterone. In a preferred embodiment, said progestogen is progesterone.

[0041] Aspect 24. An oral dosage unit, use or method for use according to aspect 20 or 21, wherein said progestogen is present in said oral dosage unit in an amount equivalent to about 25 mg to 300 mg of dydrogesterone, or said progestogen is administered in an amount equivalent to about 100 mg to 200 mg of dydrogesterone. In a preferred embodiment, said progestogen is dydrogesterone.

[0042] Aspect 25. An oral dosage unit for use, a use or a method according to any one of aspects 1 to 24, wherein a further active ingredient suitable for the prevention or treatment of hair loss is present in the oral dosage unit or a further active ingredient suitable for the prevention or treatment of hair loss is co-administered or administered before or after treatment with estetrol.

[0043] Embodiment 26. An oral dosage unit or method for use according to any one of embodiments 1 to 25, wherein the composition is formulated for oral, sublingual, buccal, or labial administration.

[0044] Embodiment 27. An oral dosage unit or method for use according to any one of embodiments 1 to 26, wherein the oral dosage unit is formulated to correspond to a daily dosage unit or is administered as a daily dosage unit, respectively.

[0045] 28. In any one of the embodiments defined herein, the dosage form can be presented as a kit-of-parts, including a packaging unit (e.g., blister pack) containing a daily oral dosage unit containing the estetrol component. Those skilled in the art further know that within the scope of the present invention, each packaging unit (e.g., blister pack) can be numbered or otherwise marked. Within the scope of the present invention, each packaging unit can be a sealed blister pack with a cardboard, paperboard, foil plastic backing and housed in a suitable cover.

[0046] Packaging units such as bottles are also envisioned. The material of the bottle is not particularly limited. In a preferred embodiment, the bottle is a glass bottle characterized by a color that can reduce or prevent degradation of the contents of the bottle, for example by ultraviolet light, while maintaining a degree of transparency that allows visual inspection of the contents of the bottle. Suitable colors include, but are not limited to, amber, cobalt, or vintage green.

[0047] Aspect 29. In certain embodiments of the kit of parts according to aspect 28, the packaging unit comprises 28 containers, or a multiple of 28 containers (e.g., 2 to 12 times 28 containers).

[0048] The above numbered aspects are further described in the following sections and in the appended claims, the subject matter of which is hereby specifically incorporated into this specification. [Brief description of the drawings]

[0049] [Figure 1]Figure showing the percentage of cell-free areas covered by normal human epidermal keratinocytes (NHEK) after contact with estetrol (E4) applied at four concentrations for different times in the presence of the growth inhibitor mitomycin C (MMC). The results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-test was performed to compare the effect of the treatment against 0.1% ethanol + MMC. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: cell-free area coverage after 6-hour contact. Right condition: cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL) + MMC; E4 10-7 M + MMC; E4 10-8 M + MMC; E4 10-9 M + MMC; E4 10-10 M + MMC. [Diagram 2] Figure showing the percentage of cell-free areas covered by normal human epidermal keratinocytes (NHEK) after contact with estetrol (E4) applied at four concentrations for different times in the absence of the growth inhibitor mitomycin C (MMC). The results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-test was performed to compare the effect of the treatment against 0.1% ethanol. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: cell-free area coverage after 6-hour contact. Right condition: cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL); E4 10-7 M; E4 10-8 M; E4 10-9 M; E4 10-10 M. [Diagram 3]Figure showing the percentage of cell-free area covered by normal human epidermal keratinocytes (NHEK) after contact with β-estradiol (E2) applied at four concentrations for different times in the presence of the growth inhibitor mitomycin C (MMC). Results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-test was performed to compare the effect of treatment against 0.1% ethanol + MMC. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: cell-free area coverage after 6-hour contact. Right condition: cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL) + MMC; E2 10-7 M + MMC; E2 10-8 M + MMC; E2 10-9 M + MMC; E2 10-10 M + MMC. [Figure 4] Figure showing the percentage of cell-free area covered by normal human epidermal keratinocytes (NHEK) after contact with β-estradiol (E2) applied at four concentrations for different times in the absence of the growth inhibitor mitomycin C (MMC). Results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-test was performed to compare the effect of treatment against 0.1% ethanol. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: cell-free area coverage after 6-hour contact. Right condition: cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL); E2 10-7 M; E2 10-8 M; E2 10-9 M; E2 10-10 M. [Diagram 5]Figure showing the percentage of cell-free area covered by normal human dermal fibroblasts (NHDF) after contact with estetrol (E4) applied at four concentrations for different times in the presence of the growth inhibitor mitomycin C (MMC). Results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-test was performed to compare the effect of the treatment against 0.1% ethanol + MMC. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: cell-free area coverage after 6-hour contact. Right condition: cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL) + MMC; E4 10-7 M + MMC; E4 10-8 M + MMC; E4 10-9 M + MMC; E4 10-10 M + MMC. [Figure 6] Figure showing the percentage of cell-free area covered by normal human dermal fibroblasts (NHDF) after contact with estetrol (E4) applied at four concentrations for different times in the absence of the growth inhibitor mitomycin C (MMC). Results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-test was performed to compare the effect of the treatment against 0.1% ethanol. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: cell-free area coverage after 6-hour contact. Right condition: cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL); E4 10-7 M; E4 10-8 M; E4 10-9 M; E4 10-10 M. [Figure 7]Figure showing the percentage of cell-free area covered by normal human dermal fibroblasts (NHDF) after contact with β-estradiol (E2) applied at four concentrations for different times in the presence of the growth inhibitor mitomycin C (MMC). Results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-test was performed to compare the effect of the treatment against 0.1% ethanol + MMC. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: Cell-free area coverage after 6-hour contact. Right condition: Cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL) + MMC; E2 10-7 M + MMC; E2 10-8 M + MMC; E2 10-9 M + MMC; E2 10-10 M + MMC. [Figure 8] Figure showing the percentage of cell-free area covered by normal human dermal fibroblasts (NHDF) after contact with β-estradiol (E2) applied at four concentrations for different times in the absence of the growth inhibitor mitomycin C (MMC). Results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-test was performed to compare the effect of the treatment against 0.1% ethanol. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: Cell-free area coverage after 6-hour contact. Right condition: Cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL); E2 10-7 M; E2 10-8 M; E2 10-9 M; E2 10-10 M. [Figure 9]Figure 1. Effect of estrogen on fibroblast migration in scratch assay. Pilot experiments suggest that E4 promotes fibroblast migration to the same extent as E2 in both mouse (A) and human (B) fibroblasts. The upper panel shows representative images of wound closure in the presence of vehicle, E2 (10-7 M) or E4 (10-7 M), and the lower panel shows the percentage of wound closure in the presence of vehicle, E2 or E4. 10-7 M E2 and 10-7 M E4 were tested in mouse fibroblasts (A), and five doses of both E2 and E4 (increasing from 10-10 M (left) to 10-6 M (right)) were tested in human fibroblasts (B). Data are presented as mean ± SEM of three independent cultures obtained from different donors. *: p<0.05. [Figure 10] Figure 1. Effect of estrogen on keratinocyte migration in a scratch assay. Under culture conditions supplemented with 15% human keratinocyte growth supplement (HKGS), the effect of E4 (10-10 M and 10-7 M) on keratinocytes appears to be higher than that of E2. X-axis: different test conditions (all concentrations expressed in M). Y-axis: percentage of wound closure. Dashed line: basal keratinocyte migration level observed for the control condition (leftmost condition; 10-7 M ethanol). [Figure 11] Figure 1 shows the effect of estrogen on immune cell polarization. Results are expressed as the relative expression of pro-inflammatory markers representing subtype M1 in (A) activated human monocytes treated with negative control (M1 vehicle), estradiol (M1 E2) or estetrol (M1 E4), and (B) non-activated mouse bone marrow-derived monocytes (BMDMs) treated with negative control (M0 vehicle), or activated mouse BMDMs treated with negative control (M1 vehicle), estradiol (M1 E2) or estetrol (M1 E4). Administration of E4 results in a switch of monocytes from subtype M1 (pro-inflammatory) to subtype M2 (healing). [Figure 12]1 shows the experimental design of Example 6. As previously described (Edelkamp et al., Molecular Dermatology, 2020 and Langan et al., Exp Dermatol, 2015), microdissected human anagen VI HFs from FUE were cultured at 37°C and 5 CO2 in minimal medium of William's E medium (Gibco, Life Technologies) supplemented with 2 mM L-glutamine (Gibco), 10 ng / ml hydrocortisone (Sigma Aldrich), 10 μg / ml insulin (Sigma Aldrich) and 1 penicillin / streptomycin mix (Gibco) to form Williams Complete Media (WCM). [Figure 13] Ki-67 / TUNEL staining. gHM: germinal hair matrix, pcHM: cortical prehair matrix. [Figure 14] A diagram showing the stages of the hair cycle. Top two images: anagen stage. Middle two images: early catagen stage. DP: dermal papilla; DPst: dermal papilla stalk; CTS: connective tissue sheath; gHM: germinal hair matrix. Bottom image: representative image of a dystrophic hair follicle (Keyence VHX900). [Figure 15] Estetrol does not induce LDH release into the medium. Medium from n=7-8 HFs / group cultured up to day 6 from donor 2 was pooled (days 1, 3, 5 and 6); Mean, GraphPad Prism 9, D'Agostino & Pearson omnibus normality test. Non-parametric analyses applied (Kruskal-Wallis test, Dunn's multiple comparison test-vehicle fixed) no significant differences. [Figure 16-1]Estetrol does not affect hair shaft production. Pooled data from n=4 female donors, mean ± SEM, GraphPad Prism 9. Kruskal-Wallis test p=0.4856; Dunn's multiple comparison test (vehicle fixed) ns; Mann-Whitney vs. vehicle *p<0.05. Macroscopic hair cycle staging was performed according to the criteria published in Langan et al., Exp Dermatol 2015. A=anagen; EC=early catagen; MC=midcatagen; dys=dystrophic catagen. [Figure 16-2] Same as above [Figure 17-1] Microscopically, HFs remain in anagen longer at all estetrol concentrations, especially at 3 μM (A, B). Pooled data from n=4 female donors, mean ± SEM, GraphPad Prism 9. Kruskal-Wallis test *p=0.0304; Dunn's multiple comparison test (vehicle fixed) ns; Mann-Whitney vs. vehicle *p<0.05. (C, D) Microscopic images: DP: dermal papilla; HMx: hair matrix; DC: dermal cup. Scale bars indicate 100 μm. [Figure 17-2] Same as above [Figure 18-1] Estetrol (3 μM) increased hair matrix keratinocyte proliferation but did not affect apoptosis (A, B). Pooled data from n=4 female donors, mean ± SEM, GraphPad Prism 9. (A): one-way ANOVA p=0.2115; Holm-Sidak multiple comparison test vehicle fixed ns; unpaired Student's t test vs vehicle *p<0.05. (B): Kruskal-Wallis test p=0.6460; Dunn's multiple comparison test (vehicle fixed) ns; Mann-Whitney vs vehicle; ns. (C) Microscopic images: Ki-67+ cells were counted in a defined area below Auber's line (germinal hair matrix, gHM), and TUNEL+ cells were counted in a defined area below Auber's line (gHM) and above (precortical hair matrix, pcHM). [Figure 18-2] Same as above [Figure 19-1]All concentrations of E4 tested tended to increase versican expression and alkaline phosphatase activity in dermal papilla (DP) cells. Pooled data from n=4 female donors, mean ± SEM, GraphPad Prism 9. (A) Versican expression in dermal papilla. Kruskal-Wallis test p=0.3529; Dunn's multiple comparison test (vehicle fixed) ns; Mann-Whitney vs vehicle ns. (B) Alkaline phosphatase activity in dermal papilla. Kruskal-Wallis test p=0.5508; Dunn's multiple comparison test (vehicle fixed) ns; Mann-Whitney vs vehicle ns. (C) Microscopic images. DP=dermal papilla. Scale bar shown indicates 100 μm. [Figure 19-2] Same as above [Figure 20] Migration analysis of DP fibroblasts revealed that all concentrations of E4 tested did not significantly affect cell density in the DP. Pooled data from n=4 female donors, mean ± SEM, GraphPad Prism 9. Kruskal-Wallis test p=0.2081, Dunn's multiple comparison test (vehicle fixed) ns; Mann-Whitney vs vehicle ns. [Figure 21] All estetrol concentrations tended to decrease cell density, with 300 nM and 3 μM E4 significantly decreasing the total number of cells in the DP stalk. Pooled data from n=4 female donors, mean ± SEM, GraphPad Prism 9. (A) Density of dermal papilla stalk cells. One-way ANOVA p=0.5092; Holm-Sidak multiple comparison test vehicle fixed ns; unpaired Student's t-test vs vehicle ns. (B) Total number of dermal papilla stalk cells. One-way ANOVA *p=0.0296; Holm-Sidak multiple comparison test vehicle fixed *p=0.0177; unpaired Student's t-test vs vehicle, *p<0.05. [Figure 22]Estetrol did not significantly affect cell density in induced bulb roots. Pooled data from n=4 female donors, mean±SEM, GraphPad Prism 9. One-way ANOVA p=0.7616; Holm-Sidak multiple comparison test vehicle fixed ns; unpaired Student's t test vs vehicle ns. [Diagram 23] In the basal layer of the bulge, 3 μM E4 significantly decreased the percentage of K15 positive cells, whereas 30 μM (significant) and 3 μM and 300 nM (trending) E4 increased their proliferation. Pooled data from n=4 female donors, mean ± SEM, GraphPad Prism 9. (A) Percentage of K15+ cells in the basal layer of the bulge. One-way ANOVA p=0.0641; Holm-Sidak multiple comparison test vehicle fixed #p=0.0288; unpaired Student's t test vs vehicle *p<0.05. (B) Percentage of Ki-67+ cells in the basal layer of the bulge. Kruskal-Wallis test p=0.1302; Dunn's multiple comparison test (vehicle fixed) ns; Mann-Whitney vs vehicle **p<0.01. [Figure 24-1] In the suprabulbar ORS, estetrol had no effect on the percentage of K15 positive cells, whereas E4 at 300 nM (significant) and 3 μM (tendency) reduced its proliferation. Pooled data from n=4 female donors, mean ± SEM, GraphPad Prism 9. (A) Percentage of K15+ cells in the suprabulbar basal layer. Kruskal-Wallis test p=0.9375; Dunn's multiple comparison test (vehicle fixed) ns; Mann-Whitney vs. vehicle ns. (B) Percentage of Ki-67+ cells in the suprabulbar basal layer. Kruskal-Wallis test p=0.7462; Dunn's multiple comparison test (vehicle fixed) ns; Mann-Whitney vs. vehicle *p<0.05. (C) Microscopic images. Scale bar=100 μm (ORS: outer root sheath). [Figure 24-2] Same as above [Diagram 25]Estetrol at 3 μM (significant) and 300 nM and 30 μM (tending) increased the percentage of CD34+ cells in the ORS on the hair bulb. (A) Percentage of CD34+ cells in the basal layer of the bulge. Pooled data from n=4 female donors, mean±SEM, GraphPad Prism 9 One-way ANOVA p=0.1011; Holm-Sidak multiple comparison test vehicle fixed *p=0.0392; unpaired Student's t-test vs vehicle *p<0.05. (B) Microscopic images. Scale bar=100 μm (ORS: outer root sheath). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0050] As used herein, the singular forms "a," "an," and "the" include both singular and plural referents unless the context clearly dictates otherwise.

[0051] The terms "comprising", "comprises" and "comprised of", as used herein, are synonymous with "including", "includes" or "containing", and these terms are inclusive or open-ended and do not exclude additional unrecited components, elements, or method steps. These terms also encompass "consisting of" and "consisting essentially of", which enjoy well-established meanings in patent terminology.

[0052] The recitation of numerical ranges by endpoints includes all values ​​and fractions falling within the particular range, as well as the recited endpoints. This applies to numerical ranges whether the numerical range is introduced by the phrase "from to," or "between and," or otherwise.

[0053] The terms "about" or "approximately", as used herein, when referring to measurable values ​​such as parameters, amounts, time intervals, and the like, are meant to encompass variations from the value relative to the specified value, such as variations of ±10% or less, preferably ±5% or less, more preferably ±1% or less, and even more preferably ±0.1% or less, from the value relative to the specified value, where such variations are appropriate to practice the disclosed invention. It will be understood that values ​​such as those modified by "about" or "approximately" are themselves specifically and preferably disclosed.

[0054] On the other hand, the term "one or more" or "at least one", e.g., one or more members or at least one member of a group of members, is clear in itself, and by way of further example, the term specifically encompasses reference to any one of said members, or any two or more of said members, e.g., any three or more, four or more, five or more, six or more, seven or more, etc. of said members, up to all of said members. In another example, "one or more" or "at least one" may refer to 1, 2, 3, 4, 5, 6, 7, or more.

[0055] The discussion of the background to the invention herein is included to explain the context of the invention, and is not intended as an admission that any of the material referred to was published, known, or common general knowledge in any country as of the priority date of any of the claims.

[0056] Throughout this disclosure, various publications, patents, and published patent specifications are referenced with an identifying citation. All publications cited herein are incorporated by reference in their entirety. In particular, the teachings or sections of such publications that are specifically mentioned in this specification are incorporated by reference.

[0057] Unless otherwise defined, all terms used in the disclosure of the present invention, including technical and scientific terms, have the meanings as commonly understood by those skilled in the art to which the present invention belongs. As further guidance, definitions of terms are included so that the teachings of the present invention can be better understood. When a particular term is defined in relation to a particular aspect of the present invention or a particular embodiment of the present invention, such relation or meaning is meant to apply throughout the specification, i.e., in the context of other aspects or embodiments of the present invention, unless otherwise defined. For example, an embodiment relating to a product can also be applied to the corresponding features of the method and use.

[0058] In the following sections, different aspects or embodiments of the invention are defined in more detail. Each aspect or embodiment so defined can be combined with any other aspect(s) or embodiment(s), unless expressly stated to the contrary. In particular, any feature indicated as being preferred or advantageous can be combined with any other feature or features indicated as being preferred or advantageous.

[0059] References throughout this specification to "one embodiment" or "an embodiment" mean that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment of the invention. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification do not necessarily all refer to the same embodiment. Furthermore, particular features, structures, or characteristics can be combined in any suitable manner in one or more embodiments, as would be apparent to one of ordinary skill in the art from this disclosure. Furthermore, even if some embodiments described herein include some features but not other features included in other embodiments, as would be understood by one of ordinary skill in the art, combinations of features of different embodiments are meant to be within the scope of the invention and form different embodiments. For example, in the appended claims, alternative combinations of the claimed embodiments are encompassed, as would be understood by one of ordinary skill in the art.

[0060] General definition and context of the invention The term "estetrol component" as used throughout the present specification includes substances selected from the group consisting of estetrol, esters of estetrol in which at least one hydrogen atom of the hydroxyl group is replaced by an acyl radical of a hydrocarbon carboxylic acid, sulfonic acid, or sulfamic acid of 1 to 25 carbon atoms, estetrol hydrates, such as estetrol monohydrate, and combinations thereof. When estetrol is mentioned throughout any part of the present specification, it is understood that any estetrol-containing component (i.e., compound) and / or estetrol derivative (e.g., estetrol ester) is also envisaged. More preferably, in the context of the present disclosure, a particularly preferred estetrol component suitable for the dosage units or cosmetic or medical uses and treatment methods described herein is estetrol (including estetrol hydrate). Most preferably, the estetrol component is estetrol monohydrate.

[0061] The term "estetrol" as used herein refers to 1,3,5(10)-estratriene-3,15α,16α,17β-tetrol or 15α-hydroxyestriol, as well as hydrates of estetrol, such as estetrol monohydrate. "Estetrol" or "E4" for short is an estrogenic steroid (PubChem CID:27125) produced by fetal human liver. Estetrol can be described as a 3-hydroxysteroid corresponding to 17β-estradiol with two additional hydroxyl groups substituted at the 15α and 16α positions. Estetrol is known to be an estrogen receptor agonist (Coelingh Bennink et al., Estetrol review: profile and potential clinical applications, Climacteric, 2008). When the estetrol component described herein refers to estetrol, the estetrol can be endogenous estetrol. Alternatively, estetrol may be chemically synthesized, synthesized by the use of (mutant) recombinant enzymes, or any combination thereof. Estetrol is alternatively known in the art as having the molecular formula: 18 H 24 O4, or may also be represented by structural formula (I): [ka] Formula (I)

[0062] In a preferred embodiment, estetrol is present or used herein as the monohydrate.

[0063] In some embodiments, the estetrol component can be the sole active ingredient or can be combined with any other cosmetic or pharmaceutical active agent known in the art for the mitigation or prevention of hair loss.

[0064] In preferred embodiments, the estetrol component is administered without a progestogen component, however, in some embodiments, for example if the patient still has a uterus, an optional progestogen component can be administered in addition to the estetrol component.

[0065] The terms "progestogen", "progestogen", "gestagen" or "gestogen" and their derivatives "progestogenic compound", as used herein and in the art, refer to any molecule that produces an effect in the subject's body similar to that of the natural female hormone progesterone. Progestogens are considered to be agonists of the progesterone receptor, and their functions have been thoroughly investigated in the art (especially reviewed in Kuhl, Pharmacology of estrogens and progestogens: influence of different routes of administration, Climacteric, 2005). Progestins are a subgroup of progestogens, and this subgroup includes synthetic progestogens. Although the above terms may be used interchangeably in the art, as a general understanding, when progestins are mentioned, they refer to synthetic progestogens.

[0066] Examples of progestins include levonorgestrel, norgestimate, norethisterone, dydrogesterone, drospirenone, 3-β-hydroxydesogestrel, 3-ketodesogestrel, 17-deacetylnorgestimate, 19-norprogesterone, acetoxypregnenolone, allylestrenol, amgestone, chlormadinone, cyproterone, demegestrel, desogestrel, dienogest, dihydrogesterone, dimethisterone, ethisterone, ethynodiol diacetate, fluorogestone acetate, gastrinon, gestodene, gestrinone, hydroxymethylprogesterone, hydroxyprogesterone, lynestrenol, mesirogestron, medroxyprogesterone, megestrol, melengestrol, nomegestrol, norethindrone, norethynodrel, and norgestrel. (including d-norgestrel and dl-norgestrel), norgestrienone, normethisterone, progesterone, quingestanol, (17α)-17-hydroxy-11-methylene-19-norpregna-4,15-dien-20-yn-3-one, tibolone, trimegestone, algestone-acetophenide, nestrone, promegestone, 17-hydroxyprogesterone ester, 19-nor- These include 17-hydroxyprogesterone, 17α-ethynyltestosterone, 17α-ethynyl-19-nortestosterone, d-17β-acetoxy-13β-ethyl-17α-ethynylgon-4-en-3-one oxime, 6β,7β;15β,16β-dimethylene-3-oxo-17-pregna-4,9(11)-diene-21,17β-carbolactone or tanaproget, and precursors of these compounds which are capable of liberating these progestogens in vivo.

[0067] Drospirenone (abbreviated as DRSP, PubChem CID: 68873) is an example of a progestin that has become increasingly widely used in combined oral contraceptives (COCs) due to its anti-mineralocorticoid and anti-androgenic effects combined with low overall off-target activity. Drospirenone-containing COCs are generally referred to as fourth generation COCs. Non-limiting examples of commercially available COCs containing drospirenone are known as "Yaz™" and "Yasmin™". An example of a progestogen-only drospirenone oral contraceptive is "Slynd™" (also commercially available). Additionally, HRT compositions containing estrogens such as estradiol and drospirenone are available, such as "Angeliq™". Drospirenone is alternatively known in the art by its molecular formula C 24 H 30 O3, or may be represented by structural formula (II): [ka] Formula (II)

[0068] It will be appreciated that when the term "drospirenone" is used herein, any drospirenone derivative is also contemplated.

[0069] By way of example and not limitation, other progestogens or progestins that have been used in COCs include norethisterone, norethindrone, levonorgestrel (LNG), norgestrel, gestodene, desogestrel, norgestimate, cyproterone acetate, dienogest, and chlormadinone.

[0070] In the context of the present invention, other compounds can be used in combination with estetrol component for administration to women with uterus.Selective estrogen receptor modulator (SERM) defines a category of such compounds that is expected to be useful complement to estetrol component in the method of the present invention.The preferred SERM for use in the context of the present invention is bazedoxifene.

[0071] In the methods and compositions further described herein, when reference is made to a "progestogen component," it should be understood that such reference includes SERMs, particularly bazedoxifene.

[0072] The term "effective amount" refers to the amount necessary to obtain a physiological effect, which can be achieved by a single administration or by repeated administrations.

[0073] A preferred subject is a female human subject.

[0074] In certain embodiments, the subject is a menopausal, peri-menopausal, and / or post-menopausal female subject.In certain embodiments, the subject is a menopausal, peri-menopausal, or post-menopausal subject with an estradiol level of less than 100 pg / ml, preferably less than 50 pg / ml, preferably less than 30 pg / ml, more preferably less than 20 pg / ml, more preferably less than 20 pg / ml, and most preferably less than 10 pg / ml.In alternative embodiments, the subject is a menopausal, peri-menopausal, or post-menopausal subject characterized by a follicle stimulating hormone concentration of at least 20 milli-international units per milliliter (mIU / ml), preferably at least 25 mIU / ml, more preferably at least 30 mIU / ml, more preferably at least 35 mIU / ml, and most preferably at least 40 mIU / ml.

[0075] "Menopausal subject", which is used interchangeably in the art with "postmenopausal subject" or "menopausal subject", refers to a female subject who has not had menstrual bleeding for one year, accompanied by a decrease or cessation of hormone (e.g. estradiol) production by the ovaries. In other words, "menopause" can be described as a biological state characterized by the impairment or cessation of the primary function of the ovaries. Menopause may be accompanied by a wide range of clinical symptoms of varying severity, including, but not limited to, vascular dysfunction, vaginal dryness, mood changes, sleep disorders, urinary incontinence, cognitive changes, physical complaints, and sexual dysfunction. Methods for diagnosing menopause have been described in the art and are therefore known to those skilled in the art (Nelson, Menopause, Lancet, 2008).

[0076] "Perimenopause" refers to the period of life that begins approximately 3-4 years before menopause and ends one year after the last menstrual period, and is characterized by persistent irregular menstrual cycles, extreme fluctuations in hormone levels, frequent anovulation, and the appearance of vasomotor symptoms (Harlow et al., Executive summary of the Stages of Reproductive Aging Workshop+10: addressing the unfinished agenda of staging reproductive aging, Menopause, 2012). The term "postmenopausal" or "post-menopausal" refers to a female subject characterized by a permanent cessation of menstrual periods. This permanent cessation is determined retrospectively after 12 months of observation of amenorrhea without any other obvious pathological or physiological cause. The term "postmenopausal" also includes menopause as a result of premature ovarian failure, surgery (e.g., oophorectomy), chemotherapy or radiation therapy for cancer, and certain diseases (e.g., infection or hypothyroidism).

[0077] The term "hair loss" as used herein corresponds to hair loss resulting from the reduction of estrogen levels in subjects, typically after menopausal transition.The term generally corresponds to female pattern hair loss and female pattern androgenetic alopecia.This may occur due to natural menopausal events, or due to early removal of uterus or any other syndrome or disorder that leads to low estrogen state.Obviously, the above only applies to female subjects, but hair loss may also occur in male subjects when estrogen levels are below normal levels, which mainly result from testosterone conversion.

[0078] The inventors have unexpectedly found that estetrol has a beneficial effect on keratinocyte proliferation and function.

[0079] The term "keratinocyte" includes a type of cell found in epithelium and epithelial hair follicle cells, including bulge keratinocytes, outer root sheath (ORS) keratinocytes, and hair bulb keratinocytes. In the outer layer of skin, keratinocytes account for about 90% of the cells. The term "increased keratinocyte function" is meant to include both increased proliferation of keratinocytes in epithelium and hair follicles, and increased, improved, or restored function of keratinocytes in epithelium and hair follicles. Such functions include, but are not limited to, thickening and moisturizing the skin, providing an adequate skin barrier and ensuring proper wound healing, promoting the growth of hair follicle cells during anagen, and epithelial-mesenchymal interactions, i.e., interactions with mesenchymal cells such as fibroblasts of the hair follicle, including dermal papilla cells.

[0080] Keratinocytes also play a role in oxidation and inflammation. Increased ROS production (especially in keratinocytes) and oxidative stress can increase DNA, protein and lipid damage, leading to premature skin aging and hair loss. Chronic low-grade inflammation damages the skin by increasing the expression of pro-inflammatory cytokines by keratinocytes, which leads to deleterious changes and premature skin aging and hair loss.

[0081] Furthermore, skin pigmentation is influenced by keratinocytes and melanocytes whose main function is the production of melanin pigment. Melanocytes are surrounded by keratinocytes, which transfer their melanin pigment to keratinocytes. Due to the close interaction and communication between melanocytes and keratinocytes, a single melanocyte can be surrounded by 36 keratinocytes, thereby influencing the keratinocytes, for example by estetrol, which also influences the melanocytes and thus pigmentation. The term "melanin" as used in this disclosure refers to a group of natural pigments produced by melanocytes localized in the epidermis. Various types of melanin have been described in the art (e.g., Wei et al., Unraveling the structure and function of Melanin through synthesis, J Am Chem Soc, 2021). "Melanogenesis" is commonly used in the art and refers to the process of melanin production. Melanogenesis, for example, is upregulated when skin is exposed to ultraviolet radiation, resulting in a darkening of skin tone.

[0082] The term "reactive oxygen species" (commonly abbreviated as "ROS") is a collective term for molecules formed from oxygen (O2). Examples for understanding are peroxide, superoxide, hydroxyl radical, singlet oxygen, and alpha oxygen. Reactive oxygen species are produced, among others, in fibroblasts and keratinocytes. While both the dermis and epidermis can protect the skin from oxidation, the epidermis contains the highest concentration of antioxidants. ROS are a negative or aggravating factor for female pattern hair loss, as they cause damage to hair follicles. Therefore, reducing ROS is important to avoid female pattern hair loss.

[0083] Keratinocytes are also a key cell type for promoting wound healing, responsible not only for wound closure and re-epithelialization, but also for regulating inflammation in the wound adjacent to immune cells. An imbalance in keratinocyte function can lead to unbalanced inflammation.

[0084] The expression "skin inflammation" or "skin inflammation" used herein should be interpreted according to the meaning generally accepted in the art, and therefore refers to any localized skin immune reaction.In the context of the present invention, the cause of skin inflammation is not particularly limited, and includes, for example, pathogens, immune system dysfunction, allergic reaction, and wound.Therefore, skin inflammation can be considered as the result of cell-cell interaction in the skin of a subject, with immune cells remaining the most important cell type.

[0085] Furthermore, the inventors have found that estetrol also favourably affects fibroblast proliferation and function.

[0086] The term "fibroblast" includes a type of cell found in the dermis and in mesenchymal hair follicle cells, including dermal papilla cells, which do not actually proliferate but increase in number through interactions with surrounding keratinocytes due to epithelial-mesenchymal interactions (EMI).

[0087] Dermal fibroblasts are the major cell type present in the dermal connective tissue (dermis). Fibroblasts interact with epidermal cells during hair growth (EMI), play a key role in skin wound healing in the interfollicular skin, and are known to have a variety of functions related to maintaining good skin health, more specifically maintaining skin thickness, skin collagen content and elasticity, and maintaining a good balance of skin moisture content / loss. Fibroblasts interact with epidermal cells in the interfollicular skin during hair growth.

[0088] The term "sebum" as used herein refers to an oily and / or waxy substance produced in the sebaceous gland by sebocytes, which are highly specialized epithelial cells that secrete sebum by holocrine secretion. Sebum is a composition that includes triglycerides, wax esters, squalene and free fatty acids, and forms an integral component of the epidermal barrier and immune system of the skin. Sebaceous glands grow from the same tissue that gives rise to the epidermis and can be classified as sebaceous glands connected to hair follicles and as independently existing sebaceous glands. The secretion of the sebaceous glands (sebum) provides emollients for the hair and skin and is under the influence of androgenic hormones. Sebum secretion declines with age and can be influenced by estrogen levels.

[0089] Anti-hair loss therapy and improvement of hair texture, hair quality and hair appearance In one aspect, the present invention provides a composition comprising an estetrol component for use in preventing or treating hair loss, as defined elsewhere herein. In another way, the present invention contemplates the use of a composition comprising an estetrol component for preventing or treating hair loss, and for improving hair texture, quality and appearance. In yet another way, the present invention contemplates the use of an estetrol component (or a composition comprising an estetrol component) for the manufacture of a medicament for preventing or treating hair loss. Finally, the present invention also provides a method of treatment for preventing or reducing hair loss, comprising administering a composition comprising administering the estetrol component to a subject systemically. Numerous methods and approaches for measuring and / or monitoring hair loss have been described in the art (e.g., reviewed by Dhurat and Saraogi, Int J Trichology, 2009), such as target area hair count ("TAHC") and target area hair width ("TAHW"). Throughout this specification and the art, the terms target area hair width and target area hair thickness can be used interchangeably.

[0090] The term "hair loss" as used herein relates to any type of hair loss in a subject, preferably an adult subject, more preferably a female adult subject. "Hair loss" as used herein refers broadly to any type of alopecia. Thus, "hair loss" as used herein encompasses androgenetic alopecia (AGA), or clinical conditions better known as alopecia areata, fibrotic alopecia, diffuse alopecia, cicatricial alopecia and alopecia universalis. Thus, the dosage units for use, uses or methods described herein can be used for the treatment of alopecia, particularly androgenetic alopecia. Androgenetic alopecia has been documented in the art in great detail on numerous occasions and is therefore known to those skilled in the art (e.g., Chin et al., Androgenetic alopecia, StatPearls, 2022). Androgenetic alopecia (indistinguishably referred to as the term "pattern alopecia") is a condition of hair loss that mainly affects the top and front of the scalp. Male pattern hair loss is generally described as a receding hairline at the front, hair loss at the top, or a combination thereof. Female pattern hair loss is typically characterized as a diffuse loss of hair volume over the scalp. In a preferred embodiment, the dosage units for use, uses or methods described herein are used for the treatment of female pattern hair loss.

[0091] The term "treatment" or "treating" is understood to refer to both therapeutic treatment of symptoms, diseases or conditions that have already developed and (clinically) manifested, and preventative or preventive measures, where the purpose of treatment is to prevent, reduce or reduce the likelihood of unwanted suffering, for example, to prevent the occurrence, progression and development of symptoms, clinical (conditions) or diseases related to hair loss.Accordingly, a further aspect of the present invention relates to an effective amount of estetrol component used to prevent hair loss in a subject, preferably a menopausal subject.Beneficial or desired clinical results include (but are not limited to) alleviation of one or more symptoms, improvement of one or more biological markers, disappearance of the spread of disease, stabilization (i.e., not worsening) of disease state, delay or slowing of disease progression, improvement or alleviation of disease state, etc.

[0092] "Prevention" or "preventing" as used in the context of the present invention refers to the avoidance of the manifestation of a condition or disease in a subject, i.e., the establishment of a preventative or prophylactic measure. Prophylactic treatment refers to treatment aimed at keeping the subject's body or elements thereof from exhibiting (the worsening of) symptoms of undesirable physiological changes.

[0093] Terms such as "therapeutic treatment" or "therapy" as used herein refer to treatments aimed at changing a subject's body or a part of a subject's body from an undesirable physiological condition, disease or disorder caused by aging to a desirable condition, e.g., a milder condition (e.g., amelioration) or even its normal health condition (e.g., restoring the subject's health, physical integrity and physical health), maintaining it in the undesirable physiological condition (i.e., not worsening) (e.g., stabilizing), or slowing down the progression to a more severe or worse condition compared to the undesirable physiological change or disorder. Measurable relief includes any statistically significant reduction in a measurable marker or symptom. Statistically significant as used herein refers to a p-value of less than 0.05, which is a commonly accepted cutoff value for statistical analysis as understood by those skilled in the art. "Treatment" encompasses both curative treatments and treatments that reduce symptoms and / or slow progression and / or stabilize a condition or disease.

[0094] Those skilled in the art recognize that to achieve an effective therapeutic treatment, a therapeutically effective dose must be administered to the subject. Thus, in the context of the present disclosure, an "effective amount" refers to the amount required to obtain a physiological effect. The physiological effect may be obtained by a single administration or multiple administrations. A "therapeutically effective amount" or a "therapeutically effective dose" refers to an amount of an estetrol component that, when administered, results in a clinically beneficial response with respect to the treatment of a subject suffering from hair loss. Similarly, a "preventively effective amount" or a "preventively effective dose" refers to an amount of an estetrol component that inhibits or delays the onset of (clinical) manifestation of hair loss. Those skilled in the art recognize that terms such as "amount," "quantity," and "level" are synonymous and have well-defined meanings in the art, and understand that they can refer to an absolute quantification of the estetrol component that is considered an effective amount, particularly for the applications described herein, or a relative quantification of the estetrol component, such as, for example, the concentration of the estetrol component relative to the subject's body weight. A suitable value or range of values ​​can be obtained from one subject or a group of subjects (i.e., at least two subjects).

[0095] It is emphasized that any value and range of estetrol component disclosed herein is suitable for different medical indications or purposes, but those skilled in the art recognize that a particular individual may experience further improved benefits from estetrol component treatment by further optimizing the optimal dosage of the component by considering a wide range of parameters, including but not limited to the nature and extent of the condition or disease to be treated, the subject's sex, the subject's age, weight, other medical indications, nutritional status, method of administration, metabolic status, interference or influence or effect of other pharmacoactive ingredients, etc. Furthermore, each individual may have a particular inherent reactivity to the estetrol component used.

[0096] The terms "subject," "patient," "individual," and the like may be used interchangeably herein and refer to a human subject, preferably a female subject who is in the menopausal or perimenopausal stage of her life.

[0097] Cosmetic methods for preventing or reducing hair loss are also contemplated, comprising the systemic administration of a composition comprising an estetrol component. In other words, the present invention also contemplates the cosmetic use of a composition comprising an estetrol component for preventing or reducing hair loss. Those skilled in the art understand that "cosmetic use" refers to "non-medical, non-therapeutic use", and therefore to use that is not intended to alleviate, prevent, or treat clinical pathology.

[0098] The therapeutic or cosmetic treatment of the present invention typically employs continuous administration of the estetrol component for a period of at least 10 days, preferably at least 20 days.

[0099] The estetrol therapeutic or cosmetic ingredient is administered in a daily dosage of about 10 mg to about 25 mg of the estetrol ingredient, preferably estetrol, and more preferably estetrol monohydrate.

[0100] In certain embodiments, the estetrol component is administered in a daily dosage of about 14 mg to about 21 mg.

[0101] In another specific embodiment, the estetrol component is administered in a daily dosage of about 14 mg to about 16 mg, or about 19 mg to about 21 mg.

[0102] In one embodiment, the therapeutic or cosmetic regimen of the present invention is administered to a non-hysterectomized patient. In a particular embodiment, the therapeutic or cosmetic regimen of the present invention comprises daily administration of about 15 mg or 20 mg of an estetrol component, preferably to a non-hysterectomized patient.

[0103] When the therapeutic or cosmetic treatment of the present invention is administered to a patient who has undergone a hysterectomy, the estetrol component is preferably administered without a progestogen component, or even as the only active ingredient.

[0104] When the therapy of the present invention is administered to non-hysterectomized patients, the estetrol component can be administered as the sole active ingredient or can be administered together with an optional progestogen component, which can be administered continuously (i.e., daily in addition to the estetrol component) or sequentially (sequentially meaning, for example, administration of the progestogen component for 10 to 14 days every month, or 14 days every three months).

[0105] The term "continuous" / "sequentially" as used herein means administering components at relatively regular intervals without (therapeutic) significant interruptions. Of course, minor interruptions that do not affect the overall effectiveness of the method of the present invention may occur, and in fact, such deviations are also encompassed by the present invention. In a preferred embodiment, more mathematically, a dosing regimen is considered continuous if the longest interval between two consecutive administrations is 3.5 times or less than the average interval. Even more preferably, the longest interval is 2.5 times or less than the average interval, and most preferably 1.5 times or less.

[0106] In one embodiment, the optional progestogen component is administered using a parenteral route, such as an intrauterine device (IUD). In one embodiment, the IUD delivers the progestogen component levonorgestrel. In one such embodiment, the IUD is a Mirena (商標) IUD or Levosert (商標) It is an IUD.

[0107] Thus, one skilled in the art will appreciate that the estetrol component can be administered with any other cosmetically or pharma- ceutical active agent for the reduction or prevention of hair loss known in the art.

[0108] In one embodiment, the therapeutic or cosmetic treatment of the present invention uses oral, sublingual, buccal, or labial administration of the estetrol component. The latter three administration methods offer the advantage that the estetrol component does not have to pass through the digestive system, avoiding first-pass liver exposure. Furthermore, these administration methods provide a rapid onset of action.

[0109] The term "sublingual" as used herein refers to a pharmacological route of administration that allows the estetrol component to diffuse through the sublingual tissue into the blood.

[0110] The term "oral" as used herein refers to a pharmacological route of administration in which the estetrol component diffuses through the tissues of the oral vestibule, i.e., the inner area of ​​the mouth between the lining of the cheeks (buccal mucosa) and the teeth / gums, and into the blood.

[0111] The term "sublabial" as used herein refers to a pharmacological route of administration that places the estetrol ingredient between the lips and gums.

[0112] In the therapeutic or cosmetic method of the present invention, the estetrol component and the progestogen component can be administered in separate dosage units. However, it is also possible, and indeed very convenient, to combine these two components in a single dosage unit.

[0113] In the therapeutic or cosmetic method of the present invention, the combination of the progestogen component and the estetrol component is suitably administered for at least 10 consecutive days.

[0114] The present invention can be suitably simplified to be implemented in the form of various administration methods known to those skilled in the art, among which is the use of a single-phase preparation comprising a dosage unit containing a fixed amount of the estetrol component and an optional progestogen component.

[0115] In embodiments of the invention in which sequential administration of the progestogen components is selected, it may be possible and convenient to combine the two components into a single dosage unit on the days they are administered.

[0116] In another embodiment of the invention, the therapy is administered to a postmenopausal subject.

[0117] In certain embodiments, the compositions described herein intended for systemic administration are used in conjunction with cosmetic compositions intended for local (i.e., transdermal) administration that do not contain estrogen, and preferably the cosmetic composition does not contain hormones.

[0118] composition The estetrol component of the present invention includes substances selected from the group consisting of estetrol, esters of estetrol in which at least one hydrogen atom of the hydroxyl group is replaced by an acyl radical of a hydrocarbon carboxylic acid, sulfonic acid or sulfamic acid of 1 to 25 carbon atoms, and combinations thereof. More preferably, the estetrol component is estetrol (including estetrol hydrate). Most preferably, the estetrol component contained in the dosage unit is estetrol monohydrate.

[0119] The estetrol component of the present invention is used in a daily dosage equivalent to about 15 mg to about 25 mg of estetrol monohydrate. In other words, if the estetrol component is not estetrol monohydrate itself, the daily dosage of the estetrol component is adjusted to obtain a pharmaceutical effect equivalent to a daily dosage of about 10 mg to about 25 mg of estetrol monohydrate, for example, about 14 mg to 16 mg of estetrol, preferably estetrol monohydrate, or about 19 mg to 21 mg of estetrol, preferably estetrol monohydrate.

[0120] In a particularly preferred embodiment of the invention, the pharmaceutical composition according to the invention is designed for daily administration, ie it represents a daily dosage unit.

[0121] For oral administration, the oral dosage units of the present invention are preferably solid or semi-solid dosage units (used interchangeably with the term "dosage form") such as tablets, capsules, cachets, pellets, pills, powders and granules. The term "solid or semi-solid dosage units" also includes capsules containing a liquid, such as an oil, in which the estetrol component of the present invention and / or the optional progestogen component is dissolved or dispersed. Tablets and equivalent solid or semi-solid dosage units can suitably contain materials such as binders (e.g., hydroxypropylmethylcellulose, polyvinylpyrrolidone, other cellulose-based materials and starches), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulose-based materials), disintegrants (e.g., starch polymers and cellulose-based materials), and lubricants (e.g., stearates and talc). These tablets and equivalent solid dosage units can be prepared, for example, by wet granulation using aqueous or organic solutions, and direct compression.

[0122] For sublingual, buccal or labial administration, the pharmaceutical composition according to the invention is preferably an orodispersible dosage unit.

[0123] The term "orodispersible dosage unit" as used herein refers to a dosage unit designed to disintegrate rapidly in the oral cavity upon contact with saliva, dispersing the estetrol component in the saliva so that it can be absorbed through the oral mucosa.

[0124] If the dosage unit is an orodispersible dosage unit, the release rate of the estetrol component from the dosage unit shall be determined in accordance with Ph. Eur. 2.9.1 ("Disintegration of tablets and capsules") and USP <701> The disintegration time can be suitably determined using, for example, a disintegration test using water as the disintegration medium in accordance with the "Disintegration Test" set forth in the "Applied Pharmacopoeia and Compositional Methods" ("Applied Pharmacopoeia and Compositional Methods"). The orodispersible solid dosage units of the present invention, when subjected to said disintegration test, typically disintegrate in less than 5 minutes, more preferably in less than 2 minutes, even more preferably in less than 1.5 minutes, even more preferably in less than 1 minute, even more preferably in less than 45 seconds and most preferably in less than 30 seconds.

[0125] In one embodiment, the dosage unit contains an estetrol component but no progestogen component.

[0126] In one embodiment, the present invention provides an oral combination daily dosage unit comprising an estetrol component and a progestogen component.

[0127] Preferably, the progestogen component is selected from the group consisting of progesterone, drospirenone, dydrogesterone, precursors of these progestogens, and mixtures thereof.

[0128] In one embodiment, the present invention provides a combination composition comprising an estetrol component together with progesterone.

[0129] In one embodiment, the present invention provides a combination composition comprising an estetrol component together with drospirenone.

[0130] In one embodiment, the present invention provides a combination composition comprising an estetrol component together with dydrogesterone.

[0131] The estetrol and progestogen components may be present in separate oral dosage units or may be combined in the same oral dosage unit.

[0132] When the progestogen component of the present invention is drospirenone, it is preferably used in a daily dosage of 0.25 mg to 10 mg, even more preferably about 0.25 mg to about 4 mg, for example about 1 mg to 4 mg, about 1 mg to 3 mg, or about 2.5 mg to 3.5 mg, preferably about 3 mg.

[0133] When the progestogen component of the present invention is dydrogesterone, it is preferably used in a daily dosage of about 5 mg to about 10 mg, more preferably in a daily dosage of about 5 mg.

[0134] When the progestogen component of the present invention is progesterone, it is preferably used in a daily dosage of 50 mg to 200 mg. In one embodiment, progesterone is used in a daily dosage of 50 mg to 100 mg when it is used continuously. In another embodiment, progesterone is used in a daily dosage of 100 mg to 200 mg when it is used sequentially, for example when it is administered for about 14 days each month.

[0135] When using different progestogen components, the daily dosage is adjusted to obtain the same pharmacological effect as a dose of 50 mg to 200 mg of progesterone.

[0136] In a preferred embodiment of the invention, the composition combines the estetrol component and the optional progestogen component in a single dosage unit, preferably a daily dosage unit. In a more preferred embodiment of the invention, the combined daily dosage unit is an oral combined daily dosage unit.

[0137] In one embodiment, the present invention provides an oral combination daily dosage unit comprising an estetrol component and progesterone.

[0138] In one embodiment, the present invention provides an oral combination daily dosage unit comprising an estetrol component and drospirenone.

[0139] In one embodiment, the present invention provides an oral combination daily dosage unit comprising an estetrol component and dydrogesterone.

[0140] In a preferred embodiment of the invention, an oral combination daily dosage unit is provided that combines estetrol in a daily dosage of about 20 mg with progesterone in a daily dosage of about 100 mg.

[0141] In a preferred embodiment, an oral combination daily dosage unit is provided comprising a daily dosage of 14 mg to 16 mg of estetrol or 19 mg to 21 mg of estetrol, preferably estetrol monohydrate, in combination with about 2.5 mg to 3.5 mg of drospirenone.

[0142] In another embodiment of the invention, the estetrol component is administered to a patient who still has a uterus in combination with a selective estrogen receptor modulator (SERM), particularly bazedoxifene. Preferably, bazedoxifene is administered in a daily dosage of about 10 mg to 50 mg. More preferably, bazedoxifene is administered in a daily dosage of about 20 mg.

[0143] In one embodiment, the present invention provides a therapy that omits the progestogen component.

[0144] The meaning of the terms "modulating the average level" or "modulating the level" or "reducing the level" or "increasing the level" as used herein should be seen as encompassing modulating, decreasing, or increasing the protein and / or mRNA expression level of the referenced substance, respectively, when compared to the reference average level in a subject having a particular condition. Protein levels in a subject can be analyzed using standard techniques, such as, for example, ELISA on a sample from the subject. mRNA expression levels in a subject can be analyzed using standard techniques, such as, for example, quantitative RT-PCR (Q-PCR) on a sample from the subject. In another embodiment, modulating includes increasing the protein or expression level.

[0145] In certain preferred embodiments, the estetrol component is contained in a solid dosage unit, preferably each solid dosage unit contains about 10 mg to 25 mg, for example about 14 mg to 21 mg, or about 14 mg to 16 mg, or about 19 mg to 21 mg, or about 15 mg, or about 20 mg of the estetrol component. In a more preferred embodiment, the estetrol component is contained in a tablet, caplet, or capsule, most preferably a tablet. In a further embodiment, the solid dosage unit is formulated to correspond to a daily solid dosage unit. In yet a further embodiment, the solid dosage unit is an oral dosage unit (i.e., a dosage unit intended to be swallowed by a subject). Thus, in certain embodiments, the medical use or method of treatment comprises daily administration of a solid dosage unit comprising an effective amount of estetrol. In certain embodiments, the effective amount of the estetrol component is contained in a single dosage unit further comprising at least one pharma- ceutical active ingredient, which may be a progestin as defined elsewhere herein, or may be an additional cosmetic or (pharmaceutical) active ingredient for the prevention or treatment of hair loss.

[0146] In alternative embodiments, the solid dosage unit is suitable for sublingual, buccal, and / or labial administration. In such embodiments, the solid dosage unit can rapidly release the estetrol component when contacted with an aqueous solvent such as saliva. Thus, in these embodiments, the solid dosage unit is an orodispersible dosage unit that releases at least about 50%, preferably at least about 60%, more preferably at least about 70%, more preferably at least about 80%, and most preferably about 80% of the estetrol component within about 5 minutes, preferably within about 3 minutes, more preferably within about 2.5 minutes, more preferably within about 90 seconds, and most preferably within about 90 seconds. The term "orodispersible dosage unit" as used herein refers to a dosage unit designed to rapidly disintegrate in the oral cavity when contacted with saliva, dispersing the estetrol component in the saliva so that it can be absorbed through the oral mucosa. Methods for determining the release rate of the estetrol component from a dosage unit are known to those skilled in the art. Standardized tests that are generally accepted in the field include Ph. Eur. 2.9.1 ("Disintegration of tablets and capsules") and USP <701> ("Disintegration") tests, for example but not limited to, using water as the disintegration medium.

[0147] In certain embodiments, the estetrol component is included in an immediate release dosage unit or composition. In alternative embodiments, the estetrol component is included in a delayed release, sustained release, or controlled release dosage unit or composition. The terms "immediate release", "delayed release", and "sustained release" or "controlled release" are clear to those skilled in the art and describe the release profile of a pharmaceutical composition. In an immediate release, the pharmaceutical composition is released from the dosage unit into the subject or patient's body almost immediately. In a delayed release dosage unit, the pharmaceutical composition is delivered to the body with a delay after administration. In a sustained release or controlled release dosage unit, the dosage unit is designed to release the pharmaceutical composition at a predetermined rate to maintain a constant drug concentration over a specific period of time. The release profile of the dosage unit can be evaluated as documented in the major pharmacopoeias. For example, immediate release is defined by the European Medicines Agency as at least 75% of the active substance dissolves within 45 minutes (European Pharmacopeia (Ph. Eur.) 9th edition). In addition, however, it will be apparent to one of skill in the art that appropriate tests and time windows may vary depending on the therapeutic range of the drug substance, solubility and permeability factors.

[0148] In alternative embodiments, the administration method that can be considered in the context of the present invention is not particularly limited, so long as it provides systemic bioavailability. This includes, but is not limited to, oral, rectal, bronchial, nasal, buccal, sublingual, vaginal, transdermal, subcutaneous, uterine, or parenteral administration, or forms suitable for administration by inhalation or spray, including administration of powder and liquid aerosol. In a preferred embodiment, the administration method is oral administration. It is understood that oral administration includes administration by oral ingestion, but also includes administration modes such as buccal and sublingual administration, optionally by orodispersible dosage units, such as, but not limited to, orodispersible tablets. In all cases, the goal is to achieve the same effective dose of estetrol in plasma (e.g., the same AUC and / or Cmax value) as with oral dosage units.

[0149] In certain embodiments, the estetrol component is formulated into a unit dosage unit, including but not limited to hard capsules, soft capsules, tablets, coated tablets (such as coated tablets or sugar-coated tablets), granules, aqueous or oily solutions, syrups, emulsions, suspensions, inhalants or suppositories, and can be provided in any suitable packaging means known in the art, non-limiting examples being lozenges, sachets, packets, bottles, films, sprays, microcapsules, implants, rods or blister packs. In embodiments in which an effective amount of the estetrol component is administered by oral administration, the oral dosage unit according to the present invention is preferably a solid or semi-solid dosage unit, such as a tablet, capsule, cachet, pellet, pill, powder and granule. Particularly preferred compositions include a combination of estetrol monohydrate in the dosage disclosed herein and excipients suitable for solid or semi-solid dosage units.

[0150] The term "solid or semi-solid dosage unit" also includes capsules containing a liquid, such as oil, in which the estetrol component and / or optional progestogen component of the present invention is dissolved or dispersed. Tablets and equivalent solid and semi-solid dosage units can suitably contain materials such as binders (e.g., hydroxypropylmethylcellulose, polyvinylpyrrolidone (povidone, PVP), other cellulosic materials and starches), diluents (e.g., lactose (monohydrate) and other sugars, starches (e.g., corn starch), dicalcium phosphate and cellulosic materials), disintegrants (e.g., starch polymers and cellulosic materials (e.g., sodium starch glycolate)), and lubricants (e.g., (magnesium) stearates and talc). These tablets and equivalent solid dosage units can be prepared by any suitable means, as fully described in the art (e.g., Kaur, Processing technologies for pharmaceutical tablets: A review, Int Res J Pharm, 2012). Non-limiting examples of processing the estetrol component when manufacturing dosage units include wet granulation using, for example, an aqueous or organic solution, direct compression, 3D printing, or coating the estetrol component onto carrier particles using an organic or inorganic solvent.

[0151] It is clear that a further aspect of the present invention relates to a pharmaceutical or cosmetic composition comprising an effective amount of estetrol component for use in any medical indication disclosed herein. The terms "formulation" or "composition" can be used interchangeably herein. It is clear that in any embodiment of one or more pharmaceutical or cosmetic compositions described herein, the composition can comprise one or more pharma- ceutically or cosmetically acceptable carriers (i.e., excipients). The term "pharma-ceutically acceptable" or "cosmetically acceptable" as used herein is consistent with the art and means compatible with other components of the pharmaceutical or cosmetic composition and not harmful to the recipient. In a particularly preferred embodiment of the present invention, the pharmaceutical composition according to the present invention is designed for daily administration, i.e., it represents a daily dosage unit. The excipients that can be used in the pharmaceutical composition are not particularly limited, and therefore include pharma- ceutical active ingredient excipients, binder excipients, carrier excipients, co-processed excipients, coating system excipients, controlled release excipients, diluent excipients, disintegrant excipients, dry powder inhalant excipients, effervescent system excipients, emulsifier excipients, lipid excipients, lubricant excipients, sustained release excipients, penetration enhancer excipients, permeation enhancer excipients, pH adjuster excipients, plasticizer excipients, preservative excipients, soluble The excipient may be one or more excipients selected from the group consisting of: stimulating agent excipients, solvent excipients, sustained release excipients, sweetener excipients, flavoring agent excipients, thickener excipients, viscosity modifier excipients, bulking agent excipients, compression excipients, dry granulation excipients, hot melt extrusion excipients, wet granulation excipients, fast release agent excipients, high bioavailability excipients, dispersion excipients, solubilization enhancing excipients, stabilizer excipients, capsule bulking excipients, or any combination thereof. Those skilled in the art will know that the use of such vehicles and drugs for pharmacoactive substances is common practice, and thus the incorporation of these excipients is known in the art. It is clear that all components used must be non-toxic at the concentration contained in the final pharmaceutical composition and must not adversely interfere with the activity of the estetrol component (which is preferably present as the main pharmacoactive component in the pharmaceutical composition).In certain embodiments, two or more excipients that one skilled in the art would classify as belonging to the same group of excipients are added to the pharmaceutical composition. In further embodiments, two or more excipients of different types that belong to different groups are added to the pharmaceutical composition. In certain embodiments, an excipient can perform more than one function and / or can be classified by one skilled in the art as belonging to different groups or types of excipients.

[0152] The compositions envisaged by the present invention may include additional skin active ingredients that can provide skin care benefits. Skin care benefits may include, but are not limited to, benefits related to the cosmetic appearance of the skin. The additional skin active ingredients may provide immediate, short-term (i.e., acute) benefits and / or long-term, sustained (i.e., chronic) benefits.

[0153] The compositions envisioned by the present invention may include additional hair loss prevention or hair care promotion active ingredients capable of providing hair care benefits known in the art. Hair care benefits include, but are not limited to, benefits related to the growth of hair as well as its cosmetic appearance. The additional hair care active ingredients may provide immediate, short-term (i.e., acute) benefits and / or long-term, sustained (i.e., chronic) benefits.

[0154] While the present invention has been described in conjunction with detailed embodiments thereof, it is evident from the above description that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. Aspects and embodiments of the invention disclosed herein are further supported by the following non-limiting examples.

[0155] The following specific experimental examples are provided in support of the claimed invention and should not be construed as limiting the scope of the invention. EXAMPLES

[0156] Example 1: Tissue distribution of estetrol after oral administration in a rat model [ 14 C]-estetrol was used to determine tissue distribution in female rats (partially pigmented and non-pigmented).

[0157] In non-pigmented female rats 14 After a single oral dose of [C]-estetrol, radioactivity concentrations were generally maximal at the initial time point of 0.5 h, with the highest concentration measured in the liver (12.5 μg equivalents / g). Radioactivity was rapidly eliminated, so that by 24 h post-dose, apart from elements of the gastrointestinal tract and bladder, only the adrenal glands, kidneys, liver, pancreas, salivary glands, and thyroid gland were quantifiable.

[0158] [To partially pigmented female rats 14 After a single oral dose of [C]-estetrol, radioactivity concentrations were highest overall at the first time point 0.5 h after oral administration, with the highest concentration measured in the liver (13.7 μg equivalents / g). Radioactivity was also rapidly eliminated, reaching the BLQ (<0.076 μg equivalents / g) in most tissues by 24 h after administration. By 7 days after administration, all analyzed tissues, including melanin-containing structures (choroid, pigmented skin), except for the liver (0.410 μg equivalents / g), were below the limit of quantification.

[0159] Protocol - Tissue distribution study in non-pigmented rats Seven female Sprague-Dawley rats were each given 14 A single oral dose of [C]-estetrol was administered. At each selected time point (see below), one animal was sacrificed (by CO2 overdose) and immediately thereafter flash frozen in hexane / solid CO2. Carcasses were retained to examine tissue distribution of radioactivity using the technique of quantitative whole-body autoradiography (QWBA).

[0160] The times for analysis were 0.5 h, 1 h, 2 h, 5 h, 8 h, 24 h and 48 h.

[0161] After completion of whole-body autoradiography sectioning, the remaining carcasses were disposed of as waste.

[0162] Radioactivity distribution in tissues was determined and quantified using a Fuji FLA-5100 fluorescent image analyzer and associated Tina and SeeScan software. Radioactivity concentrations in tissues were determined using a calibrated autoradiography microscale made by GE Healthcare. A standard curve was generated using the microscale from which tissue concentrations of radioactivity (nCi / g) were determined. These values ​​were then converted to μg equivalents / g using the specific activity of the administered formulation.

[0163] Protocol - Tissue distribution study in pigmented rats Groups of six female Lister hooded rats were each 14 A single oral dose of [C]-estetrol was administered. At each selected time point (see below), one animal was sacrificed (by CO2 overdose) and immediately thereafter flash frozen in hexane / solid CO2. Carcasses were retained to examine tissue distribution of radioactivity using the technique of quantitative whole-body autoradiography (QWBA).

[0164] The times for analysis were (0.5 h, 8 h, and 24 h, 7 days, 14 days, and 35 days).

[0165] Frozen carcasses were subjected to whole-body autoradiography.

[0166] Results in non-pigmented rats (focus on skin) When reporting concentrations, radioactivity is [ 14 C]-estetrol or [ 14 It was assumed that the radioactivity was related to any metabolites derived from [C]-estetrol. In all cases, the specific activity of the administered test compound was used to calculate concentrations. Radioactivity recovery is reported as a percentage of administered radioactivity (% dose). Similarly, radioactivity concentrations are reported as μg equivalents / g.

[0167] [ 14The radioactivity concentrations in tissues (here, only skin) and tissue:blood ratios obtained from female Sprague-Dawley rats after a single oral dose of [C]-estetrol are shown in Tables 1 and 2, respectively.

[0168] Table 1: [in vivo] 14 Radioactivity concentrations in tissues (expressed as μg equivalents / g) following a single oral dose of [C]-estetrol at a nominal dose level of 15 mg / kg [Table 1]

[0169] Table 2: [in vivo] 14 Tissue:blood ratios determined after a single oral dose of [C]-estetrol at a nominal dose level of 15 mg / kg [Table 2]

[0170] Results in pigmented rats (focus on skin) [ 14 The radioactivity concentrations and tissue:blood ratios in tissues obtained from female Lister hooded rats after a single oral dose of [C]-estetrol are shown in Tables 3 and 4, respectively.

[0171] Table 3: [intracellular matrix complexes in partially pigmented female rats] 14 Radioactivity concentrations in tissues (expressed as μg equivalents / g) following a single oral dose of [C]-estetrol at a nominal dose level of 15 mg / kg [Table 3]

[0172] Table 4: [intracellular matrix complexes in partially pigmented female rats] 14 Tissue:blood ratios determined after a single oral dose of [C]-estetrol at a nominal dose level of 15 mg / kg [Table 4]

[0173] The total radioactivity in selected tissues / organs (obtained from Caster [2] and expressed as % dose / tissue, tissue % body weight) is shown in Table 5.

[0174] Table 5: [intracellular matrix complexes in partially pigmented female rats] 14 Total radioactivity in selected tissues following a single oral dose of [C]-estetrol at a nominal dose level of 15 mg / kg Results expressed as % dose / tissue [Table 5]

[0175] Conclusion: At the first sampling time (0.5 h), based on the total dose / tissue, radioactivity was present in pigmented and non-pigmented skin at >1% of the administered dose (1.7% and 1.1%, respectively). The results show that significant E4 concentrations were achieved in the skin after oral administration, indicating that estetrol was well-reached in the skin and would be therapeutically effective.

[0176] Example 2: Effect of E4 in vitro on keratinocytes and fibroblasts, the two major cell types in the skin The aim of this study was to evaluate the effect of estetrol on the migration and proliferation capacity of human epidermal keratinocytes and human dermal fibroblasts in 2D culture and to directly compare the effects of this estrogen with another reference estrogen, estradiol (E2).

[0177] This study consists in an in vitro assay aimed at evaluating the properties of E4 and E2 at four concentrations on keratinocytes and fibroblasts, respectively. The assay involves the measurement of colony formation on standard cell-free surfaces generated from confluent monolayers of cells using a dedicated culture device (IBIDI chamber). The assay is performed in the presence and absence of proliferation inhibitors to focus on cell proliferation and migration, or migration only, respectively.

[0178] methodology Cell model - normal human epidermal keratinocytes (NHEK) Studies were performed using cultures of normal human foreskin-derived epidermal keratinocytes (NHEK, Lonza). Cells were grown in serum-free Epilife medium (ThermoFisher Scientific) supplemented with Human Keratinocyte Growth Supplement (HKGS, ThermoFisher Scientific) and antibiotics. Cells were maintained in a humidified incubator at 37°C in a 5% CO2 atmosphere.

[0179] Cell model - Normal human dermal fibroblasts (NHDF) Normal human foreskin-derived dermal fibroblasts (NHDF, ATCC) were grown in phenol-free Dulbecco's modified Eagle's medium (DMEM, ThermoFisher Scientific) supplemented with 10% fetal bovine serum (FBS, ThermoFisher Scientific), L-glutamine, and antibiotics. Cells were maintained in a humidified incubator at 37°C in a 5% CO2 atmosphere.

[0180] Assays and Analysis Cells were plated in 2-well silicone inserts with a defined cell-free gap (IBIDI chambers: IBIDI GmbH, 80209) previously inserted into 12-well culture plates. This culture device allows the creation of a standardized cell-free gap of 500 μm ± 100 μm for monitoring cell colony formation. 24 hours after seeding, when the cultures reached high confluence, the cells in the inserts were treated with mitomycin C (MMC) at 10 μg / mL for 2 hours or not. After these 2 hours, the inserts were removed and the cells were treated with E2 or E4 with or without MMC for another 2 hours. Then, if necessary, the culture medium was removed and the cells were treated with E2 or E4 without MMC for 22 hours.

[0181] For the assay, keratinocytes were plated in Epilife medium without HKGS and all treatments were performed in this medium. Fibroblasts were plated in DMEM medium containing only 2.5% FBS and treatments were performed in the absence of FBS.

[0182] E2 and E4 were each administered at four concentrations (10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M) In parallel, cells were treated with positive controls (HKGS 1% for human keratinocytes and 10 ng / ml PDGF-BB for human fibroblasts).

[0183] To monitor cell colony formation and evaluate the gap closure rate, pictures of the gaps were taken at different time points: 0 h (corresponding to the beginning of treatment with E2 or E4 and removal of the culture insert), 6 h and 24 h (corresponding to the end of treatment with E2 or E4). Pictures were taken with a microscope Zeiss (Axiover 25-10× objective) and a camera Invenio2EIII (DeltaPix - Lux-Optic). The colony-forming area was quantified from the pictures using the WimAsis platform - WimScratch software. Three pictures were taken for each insert at each time point. Three repetitions were performed for each condition, which means a total of nine pictures for each condition and each acquisition time point.

[0184] result Normal human epidermal keratinocytes (NHEK) Treatment with HKGS, used as a positive standard, allowed a significant increase in the colony-forming area in the presence and absence of MMC, thus validating the test.

[0185] In the presence of proliferation inhibitor (MMC), 10 -7 M and 10 -10E4 in M ​​significantly increased colony formation in cell-free areas compared to the ethanol control at 24 hours after treatment, indicating stimulation of cell migration (Figure 1). -7 M and 10 -10 E4 at concentrations of M significantly increased colony formation in cell-free areas compared to the ethanol control (Fig. 2 ).

[0186] In either the presence or absence of a proliferation inhibitor (MMC), E2 failed to significantly increase colony formation in cell-free areas compared to the ethanol control (Figures 3 and 4). -7 M~10 -9 M concentration range, after 24 hours of treatment, it even appears to have an inhibitory effect on gap closure. This inhibition was -8 It was significant only for the concentration of M.

[0187] Normal human dermal fibroblasts (NHDF) Treatment with PDGF-BB at 10 ng / ml, used as a positive standard, significantly increased the colony-forming area in both the presence and absence of MMC, thereby validating the assay.

[0188] In the absence of a proliferation inhibitor (MMC), E4 was unable to significantly increase colony formation in cell-free areas (Figure 6). However, in the presence of MMC at 24 h, 10 -7 M and 10 -8 E4 in M ​​was able to significantly increase colony formation in cell-free areas compared to the ethanol control (Fig. 5 ).

[0189] In the presence of a proliferation inhibitor (MMC), E2 was unable to significantly increase colony formation in cell-free gaps (Figure 7). However, in the absence of MMC at 24 h, 10 -7 M, 10 -8 M and 10 -10 E2 in M ​​increased colony formation in cell-free areas compared to the ethanol control (Fig. 8 ).

[0190] conclusion In this study, the inventors -7 M and 10 -10 We noticed that E4 in M ​​significantly increased the surface colonized by keratinocytes in culture over time. This effect was significant after 6 and 24 hours of treatment in the absence and presence of MMC, respectively. Thus, E4 may have a stimulating effect on cell proliferation as observed after 6 hours of treatment, but may also induce keratinocyte migration after a certain delay, given the differences observed in the colonized surface after 24 hours in the presence of proliferation inhibitors. In the presence of E2, no significant effect on keratinocyte proliferation or migration could be observed.

[0191] E4 and E2 showed significant activity on fibroblast cultures after 24 hours of treatment. E4 rather acted on cell migration, whereas E2 (10 -7 M and 10 -8 M), E2 appeared to have a specific effect on fibroblast proliferation (10 -7 M, 10 -8 M, and 10 -10 The results are summarized in Table 6 below.

[0192] Table 6: Activity of estetrol (E4) or estradiol (E2) on keratinocytes (NHEK) and fibroblasts (NHDF) [Table 6]

[0193] Example 3: Effects of estetrol (E4) on keratinocytes, fibroblasts, and immune cells in wound healing in an in vitro model The acute wound response involves a variety of cell types that are both activated locally and recruited from the periphery. In this pilot study, the effects of estetrol (E4) on multiple wound-associated cell types (keratinocytes, fibroblasts, and immune cells) were directly compared to those of estradiol (E2).

[0194] Keratinocyte and fibroblast experiments protocol Human skin was delivered to the laboratory in holding medium (DMEM containing 4% penicillin-streptomycin and amphotericin B solution) within 30 minutes of harvest. Once degreased, the skin was rinsed with HBSS containing 4% PSA, then with DPBS without antibiotics, then cut into thin strips and floated on 0.2% Dispase II in DPBS overnight at 4°C, after which the epidermis was manually separated from the dermis. Primary human epidermal keratinocytes and primary human dermal fibroblasts were then isolated.

[0195] Confluent wells of both primary keratinocytes and fibroblasts were subjected to a highly validated scratch wound procedure (using a 1 mL sterile filter tip). After scratching, cells were rinsed with DPBS and cell-specific medium containing treatments was added to each well. Cells were imaged on a ptychographic live cell imaging platform (Livecyte 2™, Phasefocus) for 24-48 hours. Automated tracking of individual unlabeled cells was combined with 3D cellular measurements to quantify various wound-associated cellular parameters, including scratch closure rate.

[0196] E4(10 -10 M~10 -6 Dose range-finding experiments were performed with E2, in the presence and absence of mitomycin C (MMC, to inhibit proliferation), and with vehicle as a negative control.

[0197] Fibroblasts – Results Using a widely validated in vitro fibroblast monolayer scratch assay, we demonstrated that E4 promotes in vitro wound closure in both mouse and human fibroblasts to the same extent as E2 (Figures 9A and 9B, respectively). Assays were performed in phenol red-free cell culture medium containing charcoal-stripped fetal bovine serum using fibroblasts isolated from C57Bl / 6 female mice and fibroblasts isolated from surplus abdominal skin from three female donors aged 20, 49, and 57 years.

[0198] Keratinocytes - Results The data show that the effect of estrogens (E4 and E2) on keratinocyte migration was dependent on the percentage of HKGS (Human Keratinocyte Growth Supplement) used in the culture medium. However, under culture conditions containing 15% HKGS, there was no effect of E4 (10 -10 M and 10 -7 The effect of M) appears to be greater than that of E2 (Figure 10).

[0199] Immune cell experiments Immune cell polarization was assessed in vitro in human and mouse monocytes (BMDM bone marrow-derived monocytes) using markers of M1 / TH-1 (NOS2) and M2 / TH-2 (ARG1) phenotypes.

[0200] protocol Human blood was collected under national ethical approval and with full written patient consent. Freshly isolated human blood was collected in EDTA vacutainer tubes, diluted 1:1 with PBS, and gently layered on histopaque (Merck). Immediately after centrifugation at 100×g for 30 min, the whitish buffy coat formed at the histopaque interface was aspirated and washed twice with sterile PBS (centrifugation at 100×g for 10 min). Non-contact classical monocytes (CD14++, CD16−) were isolated from the washed buffy layer cells using the Miltenyi Classical Monocyte Isolation Kit, LS columns, and MidiMACs separators (Miltenyi). Isolated cells were seeded on tissue culture plates and stimulated to differentiate with PMA.

[0201] Experiments were performed to evaluate the anti-inflammatory effects of E4 or vehicle (negative control). qPCR methodology was used to evaluate the effect of E2 and E4 on immune cell polarization using well-validated markers of pro-inflammatory (NOS2 for MI / TH-1 phenotype) and anti-inflammatory (ARG1 for ME / TH-2 phenotype).

[0202] result E4 exhibited anti-inflammatory effects and promoted the switch of mouse BMDMs (bone marrow derived monocytes) or human monocytes from subtype M1 (pro-inflammatory) to subtype M2 (healing), results are shown in Figures 11A and 11B, respectively.

[0203] Example 4: Effect of E4 on gene expression in keratinocytes and fibroblasts in an in vitro model of wound healing The healing properties of E4 were investigated at the transcriptional level by studying gene expression changes by RT-qPCR. 84-gene qPCR arrays focused on the wound healing process were used. These arrays contain genes important in the three phases of the wound healing process, including extracellular matrix (ECM) remodeling factors, inflammatory cytokines and chemokines, as well as growth factors and key signaling molecules. To highlight the potential utility of E4 on wound healing, the changes in gene expression were interpreted in a dermocosmetic context.

[0204] Cell treatment 25 cm 2 After seeding in culture flasks (T25) for 24 h, the cells were treated with E4 for 15 h. Culture conditions were identical to those used for the scratch test (see Example 2), and the cells were treated with E4 in the absence of FBS / HKGS. The cell density used for the gene expression assay was lower than that used for the scratch test, being 113636 cells / cm for keratinocytes in the culture inserts of the wound closure assay. 2 , and 100,000 cells / cm for fibroblasts. 2 15,800 cells / cm for gene expression assays 2 In practice, gene expression analysis is usually performed on under-confluent cells (during logarithmic growth phase).

[0205] Total RNA extraction 10 -7 At the end of the 15-h treatment with E4 or ethanol 0.1% used as a control, total RNA was extracted using the Qiagen RNeasy kit (Qiagen). Cells were rinsed with cold PBS and lysed in the appropriate buffer provided with the kit. Extraction was performed according to the supplier's recommendations. Harvested RNA was stored at -80°C.

[0206] RNA integrity analysis RNA concentration was determined by spectrophotometric measurement (QIAxpert, Qiagen) and RNA quality was analyzed by capillary electrophoresis (Agilent Bioanalyzer 2100-Agilent RNA 6000 Nano Kit).

[0207] cDNA synthesis Reverse transcription was performed from total RNA using the kit "RT2 First Strand Kit" (Qiagen) according to the manufacturer's instructions.

[0208] Quantitative PCR using RT2 Profiler PCR arrays To quantify the expression changes of specific markers in the cDNA population, we used the qPCR method. The RT2 Profiler PCR Array Human Wound Healing contains specific primers for 84 target genes.

[0209] Amplification of the target gene was performed according to the supplier's recommendations using "HotStart Taq DNA Polymerase" and SYBR Green as a detection method. SYBR Green is a marker that fluoresces when it intercalates between nucleic acid base pairs. Thus, the fluorescence intensity is directly proportional to the amount of amplicon produced.

[0210] qPCR was performed using the Quantstudio7 Real-Time PCR System (Applied Biosystems) and its software (QuantStudio Real-Time PCR Software v1.3, software, Applied Biosystems).

[0211] Data obtained for the E4-treated condition was compared to the ethanol control in both cell types. Threshold cycle (Ct) values ​​were normalized to the average Ct values ​​of several housekeeping genes present on the array (shown in the table below). The maximum Ct cutoff value was fixed at 36 cycles, meaning that Ct values ​​above 36 were not considered in the analysis.

[0212] result Human keratinocytes (Table 7) or fibroblasts (Table 8) were cultured at 10 -7 Treatment of M with E4 for 15 h induced certain interesting pathways involved in different phases of the wound healing process.

[0213] [Table 7] Table 7: List of genes whose expression changed after 15 hours of treatment with estetrol (E4) in cultured human epidermal keratinocytes - expressed as fold change (FC) relative to the ethanol control: FC>1: increase - FC<1: decrease

[0214] Table 8: List of genes whose expression changed after 15 hours of treatment with estetrol (E4) in cultured human dermal fibroblasts - expressed as fold change (FC) relative to the ethanol control: FC>1: increase - FC<1: decrease [Table 8]

[0215] Although small in number and amplitude, these changes in gene expression (compared to ethanol controls) suggest that E4 may promote the switch between inflammatory and proliferative / remodeling phases via downregulation of proinflammatory factors and stimulation of the coupled MMP / TIMP system.

[0216] Human fibroblasts or keratinocytes were cultured at 10 -7 Treatment of M with E4 for 15 h significantly reduced the expression of chemokines CXCL5 and CXCL11, cyclooxygenase 2 (PTGS2), and fibroblast growth factor 2 (FGF2), and enhanced the switch to the proliferative phase.

[0217] Example 5: Evidence for the antioxidant properties of E4 The purpose of this study was to identify mouse lymphoma cell line L5178Y TK + / -The objective of this study was to investigate the generation of reactive oxygen species (ROS) induced by the test product estetrol (E4) in rats.

[0218] protocol L5178Y TK in logarithmic growth phase + / - Cells were plated in black 96-well cell culture plates at 1 × 10 in 90 μL of cell culture medium. 4 The wells were plated with cells. Control and test articles were applied to the cells as 10x concentrates in 10 μL of 10% ethanol in PBS (final concentration of ethanol on the plate was 1%) in triplicate. The cells were incubated at 37°C, 5% CO2 for 3 hours and ROS generation was assessed by fluorescence using ROS reagent, which was freshly prepared by dissolving 1 ampoule (50 μg) of reagent in 70 μL DMSO and further diluting this in 2.1 mL of pre-warmed PBS. 10 μL of ROS reagent was added to each well and the plate was shaken in the dark for 30 seconds. The plate was incubated at approximately 37°C, 5% CO2 for 1 hour and 30 minutes and the fluorescence was read on a plate scanner with excitation at 492 nm and emission at 520 nm.

[0219] Three experiments were performed using negative control lactate (known not to induce ROS) and positive control hydrogen peroxide (known to increase ROS in cells) at concentrations up to 100 μM, and test article at concentrations of 1 μM, 10 μM, 50 μM, 100 μM, 1000 μM, and 3000 μM. ROS induction results for cells treated with the negative control, positive control, and test article were compared to those obtained with the untreated vehicle control.

[0220] result The negative control, lactate, did not induce ROS in any experiment at concentrations up to 100 μM when compared to the vehicle control. The positive control, hydrogen peroxide, showed a trend toward increased ROS levels after 3 hours of exposure when compared to the vehicle control.

[0221] Up to 3000 μM E4, L5178Y TK + / - Lactate caused a dose-dependent decrease in ROS detected in cells, whereas lactate up to 100 μM had no effect on ROS induction after 3 h exposure.

[0222] conclusion E4 caused a dose-dependent decrease in ROS levels in all three experiments, with the highest concentration tested (3000 μM) showing the greatest effect, suggesting that E4 acted as an antioxidant in this study.

[0223] Example 6: Hair follicle organ culture (ex vivo model) Twelve to forty-four full-length frontotemporal hair follicles (HFs) were obtained from four female donors over the age of 50. The donors were Caucasian female subjects aged 59, 62, 59, and 67 years, respectively (donor 1: 12 temporal anagen HFs; donor 2: 29; donor 3: 44; donor 4: 32). After microdissection from the skin as described (Edelkamp et al., Methods Mol Biol, 2020, 2154:105-119 and Langan et al., Exp Dermatol, 2015, Dec;24(12):903-1), HFs were placed in appropriate culture medium and allowed a 24-hour resting period to recover from the trauma of microdissection. Test substances (either vehicle (0.3% EtOH) or E4 at concentrations of 30 μM, 3 μM, or 300 nM) were added to the medium at the end of 24 hours. The total culture time was 5 to 7 days depending on the study parameters and experimental question. The experimental design of the hair follicle organ culture experiments is shown in Figure 12. Longer culture experiments can be used to analyze the ability to delay the onset of catagen.

[0224] This model allows us to evaluate whether E4 treatment can increase the duration of anagen and / or delay the onset of catagen. Clinically, hair loss is associated with a reduction in HFs in anagen or a shortened duration of anagen. Thus, promotion of anagen may limit hair loss.

[0225] The following parameters were investigated:

[0226] Ex vivo hair shaft elongation (digital brightfield microscope) This parameter reflects the growth rate of the HF and therefore correlates with HF elongation or hair shaft production.

[0227] To determine the length of the HF, each HF was measured from the end of the hair bulb connective tissue sheath to the end of the distal outer root sheath (ORS) using a digital optical microscope (VHX 900 Keyence Corporation, Osaka, Japan) at 50x magnification and associated software (Edelkamp et al., Methods Mol Biol, 2020, 2154:105-119, and Langan et al., Exp Dermatol, 2015, Dec;24(12):903-1). Measurements were taken at baseline, after a 24-hour resting period, and then every 24-48 hours for the entire duration of the experiment. Elongation is expressed as millimeters of growth and / or as percentage elongation from baseline measurements.

[0228] Proliferation and apoptosis of hair matrix keratinocytes Germ hair matrix keratinocytes proliferate mostly during anagen. Their proliferation is dramatically reduced during the anagen / catagen transition and is absent in late catagen (Langan et al., Exp Dermatol, 2015). Apoptosis of hair matrix keratinocytes is used as an additional indicator of the anagen / catagen transition.

[0229] Proliferation was assessed by quantifying the percentage of hair matrix keratinocytes (germinal hair matrix keratinocytes, below Auber's line) that were positive for the proliferation marker Ki67 (or another proliferation marker such as BrdU or EdU) in clearly defined areas, and apoptosis was assessed using TUNEL (TdT-mediated dUTP-biotin nick-end labelling) immunofluorescence (or another apoptosis marker such as activated caspase-3) in the same keratinocyte population (below Auber's line) and in precortical hair matrix keratinocytes (above Auber's line) (Langan et al., Exp Dermatol 2015) (Figure 13).

[0230] Macro- and Micro-Hair Cycle Staging and Hair Cycle Score Hair cycle staging and hair cycle score calculation are indicators of hair cycle progression and anagen-catagen transition (Langan et al., Exp Dermatol, 2015). Hair cycle staging and hair cycle score were performed at the end of the culture. The hair cycle stage of each HF was determined based on several established macroscopic and microscopic parameters (Langan et al., Exp Dermatol, 2015). For macroscopic hair cycle staging, brightfield images of live HF were taken with a digital microscope (Keyence VHX 900). Microscopic hair cycle staging was determined using Ki67 / TUNEL immunohistology and Masson-Fontana histochemistry. Hair cycle staging was analyzed by calculating the percentage of HFs in each hair cycle phase. Hair cycle scores were determined by assigning an arbitrary score to each hair cycle phase as follows: anagen: 100, early catagen: 200, mid-catagen: 300, late catagen: 400, dystrophic: 500, with higher scores indicating a greater number of HFs in catagen.

[0231] [Table 9-1] [Table 9-2]

[0232] Representative images of dystrophic hair follicles as well as anagen and early catagen are shown in FIG.

[0233] Release of lactate dehydrogenase (LDH) into the medium LDH is released from the cytoplasm of damaged cells into the culture medium. Therefore, the cytotoxicity of drugs can be estimated based on the activity of LDH present in the culture medium using a colorimetric assay (Cytotoxicity Detection Kit [LDH], Roche) as described (Gherardini et al Int J Cosmet Sci, 2019, Apr; 41(2)):164-182). Measurements were performed on supernatants collected on each day for each culture and normalized to a blank.

[0234] For maximal release, HF were treated with 1% Triton X 100 in vehicle medium at 37° C. for 30 min to induce maximal release of LDH into the medium.

[0235] Alkaline phosphatase activity - Dermal papilla (DP)-induced Alkaline phosphatase is an indicator of DP inducibility (Yang, J Dermatol Sci, 2010, Jan; 57(1):2-11). In situ activity of alkaline phosphatase was measured in DP.

[0236] Versican expression-DP inducible Versican is a large chondroitin sulfate proteoglycan molecule that is expressed in the DP of anagen HFs and decreased in catagen HFs, and its expression correlates with the inductive properties of hair (Yang, J Dermatol Sci 2010). Versican intensity was analyzed in the DPs.

[0237] CD34 expression – stem cell progeny CD34 is a marker expressed by the progeny of HF bulge stem cells. It is expressed in the outermost layer of the outer root sheath (ORS), below the isthmus (the region from the sub-bulge to above the hair bulb) (Purba et al., BioEssays, 2014, May; 36(5):513-25). CD34 expression and CD34 + The percentage of cells was analyzed in the ORS on the hair bulb.

[0238] Transmigration of DP fibroblasts Fibroblasts belonging to the DP migrate during the transition between anagen and catagen (Hawkshaw et al., Journ of Invest Dermatol, 2015, 135(8):2129-2132). At the onset of catagen, DP fibroblasts migrate through the DP stalk to the bulb root, and upon anagen induction, they migrate back to the DP. Thus, quantification of the number of DP fibroblasts present in the DP stalk and DP (Kloepper et al., Exp Dermatol, 2010, Mar; 19(3):305-12) provides a direct readout of anagen induction or catagen promotion. K15 expression - stem cells.

[0239] K15-expressing stem cells K15 is a type I cytokeratin expressed in HF bulge stem cells and their progeny (Purba et al., BioEssays, 2014). It is expressed in the bulge, infra-bulge and suprabular ORS. Bulge stem cells are identified using K15 expression, cell morphology and anatomical location (below the sebaceous gland, in the area where the arrector pili muscle attaches to the HF). K15 expression was analyzed in the basal layer of the bulge and in the suprabular ORS, and proliferation of K15-positive cells was assessed in combination with Ki67 immunofluorescence staining.

[0240] statistics Each dot represents a single hair follicle; mean ± SEM; GraphPad Prism 9; D'Agostino & Pearson omnibus normality test; for group comparisons (# p<0.05, ## p<0.01, ### p<0.001, #### p<0.0001), non-Gaussian distribution (Kruskal-Wallis test, Dunn's multiple comparison test-each group vs. vehicle), Gaussian distribution (One-way ANOVA, Dunett's or Holm-Sidak's multiple comparison test-each group vs. vehicle); pairwise comparisons (* p<0.05), non-Gaussian distribution (Mann-Whitney), Gaussian distribution (t-test); ns, not significant. If at least one group did not show a Gaussian distribution in a given group or pairwise comparison, the statistics for non-Gaussian distribution were followed.

[0241] n=3-4 donors, individual HFs. Data were first analyzed using the D'Agostino & Pearson omnibus normality test for Gaussian distribution, and outliers were identified and removed using the ROUT method (0=10 / o). If data followed a Gaussian distribution, one-way ANOVA analysis was performed, followed by Holm-Sidak's multiple comparison test (vehicle fixed and unpaired Student's t-test vs vehicle). If data were too small to determine whether data followed a Gaussian distribution, or if data did not follow a Gaussian distribution, a Kruskal-Wallis test was performed, followed by Dunn's multiple comparison test (vehicle fixed and Mann-Whitney test vs vehicle). Note that the evaluation of "growing phase only" includes data from only n=3 patients. Donor 1 does not have HF in growing phase in the vehicle group.

[0242] result - All concentrations of E4 tested did not induce HF cytotoxicity (LDH release into the medium) (Figure 15). -E4 did not alter hair shaft production (Figure 16). Microscopically, E4 at 3 μM (significantly) and at 300 nM and 30 μM (tending) prolonged the anagen phase (FIG. 17). E4 at −3 μM (significant) and at 300 nM and 30 μM (tending) increased the proliferation of hair matrix keratinocytes without affecting apoptosis of the cells (FIG. 18). All concentrations of E4 tested tended to increase versican expression and alkaline phosphatase activity in DP cells (Figure 19). -DP fibroblast migration assays revealed that all concentrations of E4 tested did not significantly affect cell density in the DP (Figure 20), all concentrations trended toward decreasing cell density, and 300 nM and 3 μM E4 significantly reduced the total number of cells in the DP stalk (Figure 21), but E4 had no significant effect on cell density in the induced hair bulb root (Figure 22). In the basal layer of the bulge, 3 μM E4 significantly decreased the percentage of K15 positive cells, whereas 30 μM (significantly) and 3 μM and 300 nM (tendency) E4 increased their proliferation (FIG. 23). - In the hair bulb ORS, E4 had no effect on the percentage of K15 positive cells, but 300 nM (significant) and 3 μM (tendency) of E4 reduced their proliferation (FIG. 24). E4 at −3 μM (significantly) and at 300 nM and 30 μM (tendingly) increased the percentage of CD34 positive cells in the suprabublic ORS (FIG. 25).

[0243] Observations and Conclusions In the experiments reported here, we investigated the potential effects of the estrogenic compound E4 on hair cycle, hair matrix keratinocytes, DP induction and DP fibroblast emigration, stem cell maintenance, and progeny generation in the context of hair growth promotion. The experiments confirmed that the tested concentrations of E4 did not induce HF cytotoxicity (release of LDH into the medium). Most importantly, data from four individual donors revealed that E4 tended (300 nM and 30 μM) and significantly (3 μM) extended anagen ex vivo. The significant anagen extension effect of 3 μM E4 was further supported by the decrease in cell density in the DP stalk, since DP fibroblasts accumulate in this particular compartment during their emigration from the DP in catagen (Kloepper et al., Exp Dermatol. 2010). The anagen extension effect was also supported by a significant increase in hair matrix keratinocyte proliferation after treatment with 3 μM E4.

[0244] The data suggested that the anagen-prolonging effect of E4 may be mediated, at least in part, by stimulation of DP fibroblast-inducible cells. Indeed, all concentrations of E4 tested appeared to tend to upregulate alkaline phosphatase activity and versican expression in DP.

[0245] While 3 μM E4 appeared to trend-increase the proliferation rate of multipotent HF stem cells in the bulge, it significantly reduced the percentage of K15-positive cells. However, this treatment beneficially affected the generation and / or activity of stem cell progeny in the ORS on the hair bulb. Specifically, 3 μM E4 trend-increased the number of proliferating K15-positive cells and significantly increased the percentage of CD34-positive cells, the latter further supporting the anagen-extending effect of E4 (Purba et al., 2014).

[0246] Taken together, these experiments further encouraged the exploration of 3 μM E4 treatment to promote hair growth. E4 may have the potential to maintain anagen and prevent HFs from shrinking. The above experiments will be repeated with affected and unaffected terminal and mid-microdissected intact HFs from FPHL patients, which is expected to show beneficial effects of E4 treatment.

[0247] Example 7: Clinical Study to Evaluate the Effect of Estetrol Treatment on Hair Loss in Menopausal (Peri- and Post-Menopausal) Women Initiate a randomized, double-blind, placebo-controlled, phase 2 (pilot) study to evaluate the efficacy of estetrol in postmenopausal women with androgenetic alopecia and assess its effect on hair parameters.

[0248] Study design: This randomized, double-blind, placebo-controlled, phase 2 (pilot) study will consist of two parts, obstetrics-gynecology and dermatology, which will be conducted at two different laboratories specializing in each specialty.

[0249] Determination of subject eligibility includes classification of hair loss pattern using the Sabin Scale.Subjects are randomly assigned to one of two treatment groups and receive either 20 mg of E4 as the monohydrate or a placebo.

[0250] MHT efficacy investigations will include assessment of lipid and glucose metabolism, as well as bone turnover. Additionally, the Clinical Global Impression scale (CGI) will be used to assess overall improvement by the investigator. Dermatological investigations will include quantitative hair measurements, Subject Self-Assessment (SSA), and Investigator's Global Assessment (IGA) of hair growth. Additionally, subjects will complete Menopause-Specific Quality of Life (MENQOL) and Dermatology Life Quality Index (DLQI) questionnaires. Safety of estetrol (E4) will be assessed throughout the study in all subjects.

[0251] Number of participants (planned: 60 participants (treatment group 1: 30, treatment group 2: 30) The sample size was 20 hairs / cm between groups in target area hair counts (TAHC). 2 To detect a difference, a standard deviation of 25 fibers / cm 2 and taking into account the use of a non-parametric approach (Sauerbronn, int J Gynaecol Obstet, 2000, Jan; 68(1):35-41), a two-sided type I error of 5% and a power of 80% were determined.

[0252] Efficacy variables Efficacy variables for menopausal hormone replacement (MHT): Assessment of effects on lipid and glucose metabolism, and bone turnover, as assessed by laboratory tests of fasting blood samples. CGI Evaluation In addition, subjects will complete a MENQOL questionnaire.

[0253] Dermatological Efficacy Variables: Dermatological measurements and assessments will be performed at baseline (at screening or subsequent visits) and at visits (eg, at weeks 12 and 24, months 4, 8, and 12). The top dermatological efficacy variables were: Target area hair count (TAHC), Hair growth assessment (HGA). Other variables are considered as secondary variables. The hair parameters are evaluated using the following measurements:

[0254] Digital image analysis from standardized close-up photography (HairMetrix Phototrichogram, Canfield) for quantitative hair measurement: Target area hair count (TAHC) and Target area hair width (TAHW) separately for non-vellus and vellus / vellus-like (reduced) hair. To aid in standardized close-up photography, scalp microdot tattoos will be administered at baseline and during one or more visits.

[0255] Standardized Global Photography for SSA and IGA using global photographs of the subject's scalp taken at baseline via the Canfield camera device software and comparison of each with real-time global photographs made immediately available on the Canfield review software installed on a Canfield-supplied laptop.

[0256] Subjects' self-assessment of scalp hair growth consisted of three assessments: Hair Growth Assessment (HGA) (Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, et al. A versus multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% Minoxidil topical foam placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57:767-74)

[0257] Scalp hair growth will be compared to baseline (Visit X) using the following 7-point scale: [-3] Significant decrease [-2] Moderate decrease [-1] Slight decrease [0] No change [1] Slight increase [2] Moderate increase [3] Significant increase This is for the statement: "My scalp hair growth compared to baseline is..."

[0258] Efficacy Variables: Hair Growth Index (HGI): Hair Growth Index (HGI)(Gubelin Harcha W, Barboza Martinez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70:489-98 (see e3)

[0259] Scalp hair growth will be compared to baseline (Visit X) with a Health Outcomes Questionnaire using the following 7-point scale: [-3] Very low [-2] Moderately low [-1] Slightly less [0] Same amount [1] Slightly more [2] Moderately common [3] Very common This answers three questions: "Since starting treatment, when I look at areas of hair loss, I can see... (the scalp)." "Since starting treatment, my hair now covers... (my scalp)." "Since starting treatment, the appearance (thickness / quality / quantity) of the hair on my head in the areas of reduced volume has...".

[0260] Hair Growth Satisfaction Scale (HGSS) (See Gubelin Harcha W, Barboza Martinez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70:489-98 e3)

[0261] Scalp hair growth / appearance will be compared to baseline (Visit X) using the following 7-point scale: [-3] Very dissatisfied [-2] Unsatisfactory [-1] Somewhat dissatisfied [0] Neutral / Neither satisfied nor dissatisfied [1] Somewhat satisfied [2] Satisfaction [3] Very satisfied This is in response to five questions: "How satisfied are you with the way you feel about..." The overall look of your hair. The appearance of an area (or areas) of hair volume loss in the treatment areas on your head. The amount of scalp visible in the treatment area. The amount of hair in the treatment area. Hair growth in the treatment area.

[0262] The Investigator's Global Assessment (IGA) of scalp hair growth is performed using the following 7-point scale: [-3] Significant decrease [-2] Moderate decrease [-1] Slight decrease [0] No change [1] Slight increase [2] Moderate increase [3] Significant increase

[0263] In addition, subjects can answer questions about the DLQI and Hairdex™ (see Fischer TW, Schmidt S, Strauss B, Elsner P. Hairdex Ein Instrument zur Untersuchung der krankheitsbezogenen Lebensqualitaet bei Patienten mit Haarerkrankungen. Hautarzt., 2001 Mar; 52 (3):219-27).

[0264] Safety variables: Medical and gynecological history Physical examination Gynecological examination Breast Examination Dermatological examination of the skin Vital signs Electrocardiogram (ECG) Papanicolaou (PAP) test Transvaginal Ultrasound (TVUS) Mammography Laboratory Testing: Fasting blood sampling for the following purposes: Hematology / Chemistry Lipid / glucose parameters for participation Blood collection for the purposes of: Follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH) for participation Urine pregnancy test Prior and concomitant medications will be identified and monitored throughout the entire study period. Adverse events (AEs) will be monitored and collected throughout the study period.

[0265] Participation criteria: Subjects will be assigned to treatment if they meet all of the following entry criteria: 1. A signed and dated completed informed consent form and all necessary privacy authorizations, prior to the start of any study procedures and after the nature of the study has been explained to you in accordance with local regulatory requirements; 2. Females aged ≥40 years and ≤65 years at screening; 3. For subjects with a hysterectomy: A documented hysterectomy must have occurred at least 6 weeks prior to the start of screening. The hysterectomy can be total or subtotal (i.e., without removal of the cervix); 4. For non-hysterectomized subjects: 2-layer endometrial thickness ≤ 4 mm on TVUS; 5. Seeking treatment to relieve VMS associated with menopause; 6. Body mass index is 18.5 kg / m 2 More than 35.0 kg / m 2 below; 7. No significant signs of disease on mammograms taken during screening or within 9 months prior to starting screening 1 ; 8. Postmenopausal status defined as any of the following: a. For non-hysterectomized subjects: At least 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with a serum FSH level >40 mIU / mL (value obtained after withdrawal of estrogen / progestin-containing medications (if applicable); see Exclusion Criteria 18 and 20). or 6 weeks after bilateral oophorectomy2 with or without hysterectomy; b. Regarding hysterectomy eligibility: serum FSH >40 mIU / mL (value obtained after withdrawal of estrogen / progestin-containing medications (if applicable), see exclusion criteria 18 and 20); Or bilateral oophorectomy 2 at least 6 weeks after surgery; 9. Good physical and mental condition, in the judgment of the responsible physician, based on medical history, physical and obstetric-gynecologic examination, and clinical evaluation prior to Visit 1; 10.Able to understand and comply with protocol requirements, instructions, and limitations stated in the protocol; 11. Be able to complete and cooperate with the examination diary and questionnaire. 12. Non-smoker (including e-cigarettes) for at least 1 year

[0266] Further inclusion criteria taking into account skin conditions: 13. Decreased hair density on the parietal area relative to the temporal and occipital areas, with scalp hair density in the relevant density areas ranging from n.2 to n.6 on the Sabin scale. 14. Subject is willing to maintain the same hairstyle, hair length, and hair color throughout the study period (meaning the same hair dyeing interval prior to the approved photograph at Screening / Baseline). 15. Subject agrees to continue other holistic hair care products and regimens throughout the study. 16. Subject agrees to maintain the same dietary and supplement patterns.

[0267] 1 Subjects must have a Breast Imaging-Reporting And Data System (BI-RADS) score of 1 or 2 to be enrolled in the study. Unsatisfactory mammogram results, i.e., BI-RADS 0, are not acceptable and require further evaluation. The laboratory should obtain a copy of the official report on the subject's study file. If a mammogram is performed as part of the study, a digitized image should be obtained. 2 A report or statement on letterhead from the subject's physician verifying that both ovaries have been removed is required.

[0268] Exclusion criteria: Subjects will not be assigned to treatment if they meet one of the following exclusion criteria: 1. History of malignancy, except for basal cell carcinoma or nonmetastatic squamous cell carcinoma if diagnosed >1 year prior to the screening visit 3 ; 2. The investigator finds any clinically significant findings on breast examination and / or mammography that are suspicious for breast cancer, which may require further clinical investigations to eliminate the cancer (but simple cysts confirmed by ultrasound are acceptable); 3. PAP testing with atypical squamous cells of undetermined significance (ASC-US) or worse (low-grade squamous intraepithelial lesion [LSIL], atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion [HSIL] [ASC-H], HSIL atypia or malignant cells) in partial hysterectomized and nonhysterectomized subjects 4 NOTE: ASC-US is acceptable if reflex human papillomavirus (HPV) testing is performed and negative for high-risk oncogenic HPV subtypes 16 and 18; 4. Regarding non-hysterectomy subjects: a. Presence of uterine cancer, endometrial hyperplasia; b. Presence of endometrial polyp(s); c. Undiagnosed vaginal bleeding or undiagnosed abnormal uterine bleeding; d. Endometrial ablation; e. Uterine / endometrial abnormalities that contraindicate the use of estrogen and / or progestin therapy in the opinion of the investigator, including the presence or history of adenomyosis or significant fibroids; 5. Systolic blood pressure (BP) > 139 mmHg and diastolic BP > 89 mmHg during screening 5 ; 6. History of venous or arterial thromboembolism (e.g., superficial or deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, angina pectoris, etc.) or a first-degree family history of venous thromboembolism (VTE); 7. History of known acquired or congenital coagulation disorders or abnormal clotting factors (including known thrombophilia); 8. Laboratory test results show fasting glucose >125 mg / dL and / or glycated hemoglobin >7.5% 6 ; 9. Dyslipoproteinemia (LDL > 190 mg / dL and / or triglycerides > 300 mg / dL) 7 ; 10. Presence or history of gallbladder disease (except for those who have had a cholecystectomy); 11. Systemic lupus erythematosus; 12. Any malabsorption disorder, including gastric bypass surgery; 13. History of acute liver disease within 12 months prior to screening, or presence or history of chronic or severe liver disease [alanine transaminase (ALT) or aspartate transaminase (AST) >2x upper limit of normal (ULN), bilirubin >1.5x ULN] or liver tumor; 14. Chronic or current acute renal dysfunction (estimated glomerular filtration rate <60 mL / min); 15. Positive human immunodeficiency virus (HIV), hepatitis B, or hepatitis C serology; 16. Porphyria; 17. Diagnosis or treatment of major psychiatric illness (e.g., schizophrenia, bipolar disorder, etc.) in the judgment of the responsible physician; 18. Use of the following estrogen / progestin-containing drug(s): For vaginal nonsystemic hormonal products (rings, creams, gels), 1 week prior to screening; b. For vaginal or transdermal estrogen or estrogen / progestin products with systemic effects, 4 weeks prior to the start of screening; c. For oral estrogen and / or progestin products, and / or selective estrogen receptor modulator therapy, within 8 weeks prior to the start of screening; d. for intrauterine progestin therapy, 8 weeks prior to screening; e. Progestin implant or estrogen-only injectable pharmaceutical therapy within 3 months prior to screening; f. estrogen pellet therapy or progestin injectable pharmaceutical therapy, 6 months prior to screening; 19. Use of androgen / dehydroepiandrosterone (DHEA)-containing drugs: For oral, topical, vaginal, or transdermal androgens, 8 weeks prior to the start of screening; b. For implantable or injectable androgen therapy, 6 months prior to screening; 20. Use of phytoestrogens or black cohosh for the treatment of VMS within 2 weeks prior to screening; 21. Not cooperating with the discontinuation of all hormonal products listed in Exclusion Criteria 18, 19 and 20 during study participation; 22. Inadequately treated thyroid dysfunction. Subjects with low or high TSH are accepted as long as free thyroxine (T4) is within normal range at screening. 8 . 23. History or presence of allergy / intolerance to the product under investigation or to this class of drug or any component thereof, or history of drug or other allergy which in the opinion of the responsible investigator contraindicates the subject's participation; 24. History of alcohol or drug abuse (including marijuana (even if legal)) or dependence during the 12 months prior to screening, as determined by the investigator based on reported observations; 25. Employees of the sponsor or CRO, or employees under the direct supervision of the Investigator and / or directly involved in the study; 26. Subject with known or suspected history of clinically significant systemic disease, unstable medical illness, life-threatening illness, or current malignancy that, in the opinion of the Investigator, would pose a risk to the subject; 27. Participated in a clinical trial of another investigational drug within 1 month (30 days) or received an investigational drug within 1 month (30 days) prior to the start of screening; 28. The patient is deemed ineligible by the investigator for any reason.

[0269] Further exclusion criteria considering the impact on hair condition: 29. The subject has any dermatological disorder in the target area of ​​the scalp that may interfere with the application of the IMP or test method, such as fungal or bacterial infection, seborrheic dermatitis, psoriasis, eczema, folliculitis, scarring, or scalp atrophy. 30. The subject has a local, systemic (e.g., uncontrolled thyroid disease, certain genetic disorders affecting hair growth or pattern), or skin medical condition requiring surgical treatment that, in the opinion of the Investigator, may or will interfere with the evaluation of the IMP. 31. Subject has a history or any signs of hyperandrogenemia (e.g., excessive facial / pubic / umbilical hair growth, severe acne, excessive testosterone levels in medical history). 32. The subject has a current or recent history (within 6 months) of using hair extensions, non-breathable wigs, or hair bonding. 33. The subject underwent a scalp hair transplant at any time. 34. Subject has a history of active hair loss due to diffuse telogen effluvium, alopecia areata, cicatricial alopecia, trichotillomania, or a condition / disease other than AGA. 35. Subject has a current or recent history (within 6 months) of severe dietary or weight change or has an eating disorder(s), any history of weight loss surgery (gastric bypass, gastric sleeve, gastric stapling), macro- or micro-nutrient deficiencies within the past 6 months (i.e. clinically significant iron deficiency, protein deficiency confirmed by laboratory testing), and / or a current diagnosis of any absorption disorder (i.e. celiac, irritable bowel syndrome, etc.). 36. Subject has used any of the following topical preparations or treatments on the scalp: a) Topical scalp treatments for hair growth including minoxidil, hormone therapy, antiandrogens, or other medications known to affect hair growth within 12 weeks prior to baseline (Visit 2). b) Within 4 weeks prior to Baseline (Visit 2), use of topical scalp over-the-counter (OTC) or cosmetic treatments known or reasonably believed to affect hair growth (e.g., Maxilene, Nioxin, Foltene, etc. brands) or hair health or hair growth products containing saw palmetto, copper, etc. c) Topical scalp treatments that may concomitantly affect hair growth, including (but not limited to) corticosteroids, pimecrolimus, tacrolimus, and retinoids, within 4 weeks prior to baseline (Visit 2). d) Scalp procedures (surgical, laser, light, or energy therapy, microneedling, etc.) within 6 months prior to baseline (Visit 2). e) Platelet-rich plasma (PRP) treatment of the scalp within one year. 37. Subject has used the following systemic medications or procedures: a) Beta-blockers, cimetidine, diazoxide, or corticosteroids (including intramuscular and intralesional injections) within 12 weeks of Visit 2 / Baseline. Inhaled, intranasal, or ophthalmic corticosteroids are permitted as long as use is stable (defined as unchanged dose and frequency for at least 4 weeks prior to Baseline (Visit 2)). b) Retinoid, isotretinoin, vitamin A intake >10,000 IU per day, or cyclosporine therapy within 6 months prior to baseline (Visit 2). c) Any 5-alpha reductase medication (i.e., finasteride (e.g., Propecia™), dutasteride, or similar product(s)) within 12 months prior to Baseline (Visit 2). d) Chemotherapy or cytotoxic agents within the past 5 years. e) Radiation therapy to the scalp at any time. f) Antiandrogens within 6 months prior to Baseline (Visit 2); concomitant use of antiandrogens (e.g., cyproterone acetate, chlormadinone acetate) and birth control pills is permitted as long as use is stable (defined as no change in dosage and frequency for at least 3 months prior to Baseline (Visit 2)). g) Any other systemic therapy within 3 months prior to Baseline (Visit 2) or during the study, including but not limited to, hair growth or hair health products that are spironolactone, vitamins (including biotin intakes greater than 5 mg / day) or homeopathic supplements, or other steroid hormones (in any form), including anabolic steroids, that in the opinion of the Investigator may significantly affect the subject's hair or hair growth.

[0270] 3 The only exclusions are basal cell carcinoma of the skin or nonmetastatic squamous cell carcinoma of the skin, either of which was diagnosed >1 year prior to the subject's screening. 4 As indicated in writing within 18 months prior to screening or by the time of testing at screening. 5 BP measurements may be repeated at screening if values ​​remain outside the inclusion criteria after an additional 5-10 minutes of sitting. The last measurement will be used to determine eligibility. Subjects with mild-to-moderate hypertension controlled on a stable antihypertensive regimen may be enrolled if they meet all inclusion / exclusion criteria. Subjects using methyldopa- or clonidine-containing antihypertensive medications will not be included. 6 Laboratory values ​​of fasting glucose and glycated hemoglobin assessed over the past 6 months, as well as during drug withdrawal and screening, must be considered. 7 Subjects using lipid-lowering therapy must be on a stable dose for at least one month prior to screening. 8 A reflex T4 test should be performed at screening only if the screening TSH is outside the normal range.

[0271] Statistical methods: Analyses will be performed on intention-to-treat and per-protocol populations. Categorical factors will be summarized using frequencies and percentages, and continuous measures will be described using means and standard deviations.

[0272] For normally distributed data, the significance of within-group changes from baseline is estimated from Student's t-distribution, and between-group changes from baseline are compared using an unpaired t-test. Results are presented as means and 95% confidence intervals. For data not normally distributed, equivalent nonparametric methods are used: Wilcoxon signed-rank test for within-group changes from baseline, and Mann-Whitney U test for between-group comparisons. Results are presented as median, minimum and maximum.

[0273] Analyses will be performed using SAS software (Stat version 15.2; SAS Institute, Cary, NC, USA) with a significance level of 0.05. No adjustment for multiplicity of tests will be made in this exploratory POC study. [Explanation of symbols]

[0274] Drawing translation Figure 1 Acellular area covering (% relative to the acellular area at t=0h) Figure 2 Acellular area covering (% relative to the acellular area at t=0h) Figure 3 Acellular area covering (% relative to the acellular area at t=0h) Figure 4 Acellular area covering (% relative to the acellular area at t=0h) Figure 5 Acellular area covering (% relative to the acellular area at t=0h) Figure 6 Acellular area covering (% relative to the acellular area at t=0h) Figure 7 Acellular area covering (% relative to the acellular area at t=0h) Figure 8 Acellular area covering (% relative to the acellular area at t=0h) Figure 9 A Vehicle Mouse Fibloblasts % closure % closure Veh Vehicle B Vehicle Human Fibroblasts % closure % closure V Vehicle Figure 10 Vehicle Figure 11 A Human monocytes M1 Veh M1 Vehicle B Mouse BMDM M0 Veh M0 Vehicle M1 Veh M1 Vehicle Figure 12 resting period day 0 Microdissection of full-length HFs from scalp skin or FUEs Froze 3 anagen D0 HFs Three HFs were frozen at day 0 of the growth phase. 48-well plate (1 HF / well) day 1 Treatment start day 3 Medium change day 5 Decision to continue culture if more than 20% of HFs in the vehicle group are still in anagen. Day 6 Close ex vivo culture Complete ex vivo culture Embedding of HFs in cryomatrix for protein analysis Figure 14 Masson Fontana Anagen growth period Early catagen Figure 15 HF-ML-22-023 LDH measurements Max release Maximum release LDH Release [arbitrary units] Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol HF-ML-22-023 % cytotoxicity LDH release [%] LDH release [%] Figure 16 Hair shaft production (Pooled donors) Day 3 Day 5 Day 6 Fold change of % of elongation (Vehicle normalized to 1) Vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol Figure 17 A Microscopic hair cycle staging (Pooled donors) % of hair follicles in each stage dystrophic Mid catagen Early catagen Anagen growth period Vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol B Pooled microscopic hair cycle score Arbitrary units vehicle normalized to 1 Vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol C Vehicle early catagen 30μM Estetrol anagen growth period D 3 μM Estetrol anagen growth period 300nM Estetrol Figure 18 A Pooled hair matrix keratinocyte proliferation Pooled hair matrix keratinocyte proliferation Fold change of Ki-67+ hair matrix keratinocytes vehicle normalized to 1 vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol B Pooled hair matrix keratinocyte apotosis Fold change of TUNEL+ hair matrix keratinocytes vehicle normalized to 1 vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol C Vehicle Figure 19 A Versican expression (Pooled donors) Fold change of fluorescence intensity [Arbitrary units] vehicle normalized to 1 vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol B Pooled alkaline phosphatase activity (Pooled donors) Fold change of alkaline phosphatase activity [Arbitrary units] vehicle normalized to 1 vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol C 3 μM Estetrol Vehicle 300nM Estetrol 30μM Estetrol Figure 20 Density of dermal papilla cells (Pooled donors) Fold change of cell number / μm2 in the dermal papilla vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol Figure 21 A Density of dermal papilla stalk cells (Pooled donors) Fold change of cell number / μm2 in the dermal papilla stalk 2 Fold change in vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol B Total number of dermal papilla stalk cells (Pooled donors) Fold change of cell number in the dermal papilla stalk vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol Fig. 22 Pooled density of dermal cup cells Pooled density of hair bulb root cells Fold change of cell number / μm 2in the dermal cup Fold change in cell number / μm2 in the hair bulb root vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol Fig. 23 A Percentage of K15+ cells in the bulge basal layer (Pooled donors) Fold change of % of K15+ in DAPI cells Fold change of % of K15+ in DAPI cells vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol B Percentage of Ki-67+ cells in the bulge basal layer (Pooled donors) Fold change of % of Ki67+ in K15+ cells vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol Fig. 24 A Percentage of K15+ cells in the suprabulbar basal layer (Pooled donors) Fold change of % of K15+ in DAPI cells Fold change of % of K15+ in DAPI cells vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol B Percentage of Ki-67+ cells in the suprabulbar basal layer (Pooled donors) Fold change of % of Ki67+ in K15+ cells vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol C vehicle 30μM Estetrol 3 μM Estetrol 300nM Estetrol Fig. 25 A Percentage of CD34+ cells in the bulge basal layer (Pooled donors) Fold change of % of CD34+ in DAPI cells Fold change of % of CD34+ in DAPI cells vehicle 300nM Estetrol 3 μM Estetrol 30μM Estetrol B Vehicle 3 μM Estetrol 30μM Estetrol 300nM Estetrol

Claims

1. 13. An oral dosage unit comprising an amount of estetrol component equivalent to about 10 mg to about 25 mg of estetrol for use in the prevention or treatment of hair loss.

2. A method for preventing or treating hair loss comprising orally administering a composition comprising about 10 mg to about 25 mg of an estetrol component.

3. 1. Use of an effective amount of an estetrol component in the manufacture of a composition or medicament for the prevention or treatment of hair loss, wherein the estetrol component is used in an amount equivalent to about 10 mg to about 25 mg of estetrol.

4. (Category?) 4. The oral dosage unit for use according to claim 1, the method according to claim 2 or the use according to claim 3, wherein the prevention or treatment results in an improvement or maintenance of hair texture, quality and / or appearance, preferably wherein the treatment comprises or results in an improvement in Target Area Hair Count (TAHC) and / or Target Area Hair Width (TAHW).

5. 4. The oral dosage unit for use, method or use according to any one of claims 1 to 3, wherein said prevention or treatment comprises preventing hair loss, reversing hair loss, slowing hair loss, reducing hair loss or increasing hair growth.

6. (Multi-Multi) 6. The oral dosage unit for use, method or use according to any one of claims 1 to 5, wherein said hair loss is hormone-related hair loss, more preferably hair loss caused by menopausal hormone deregulation such as estrogen deficiency, preferably female pattern hair loss or androgenetic alopecia (AGA).

7. (Multi-Multi) An oral dosage unit for use, method or use according to any one of claims 1 to 6, wherein said prevention or treatment increases the function and / or growth of keratinocytes, and in this regard preferably increases the function and / or growth of epidermal keratinocytes (KC), such as those belonging to the bulge, outer root sheath (ORS) or hair bulb.

8. (Multi-Multi) 8. An oral dosage unit for use, method or use according to any one of claims 1 to 7, wherein said prevention or treatment increases the function and / or growth of hair follicle mesenchymal fibroblasts and, in this regard, increases the function and / or growth of dermal papilla (DP) cells.

9. (Multi-Multi) 9. An oral dosage unit for use, method or use according to any one of claims 1 to 8, wherein said prevention or treatment means delaying the onset of regression or preventing regression.

10. (Multi-Multi) An oral dosage unit for use, method or use according to any one of claims 1 to 9, wherein said prevention or treatment refers to the promotion and / or prolongation of anagen.

11. (Multi-Multi) An oral dosage unit for use, method or use according to any one of claims 1 to 10, wherein said prevention or treatment refers to the restoration and / or promotion of epithelial-mesenchymal interactions between hair follicle cells.

12. (Multi-Multi) 12. An oral dosage unit for use, method or use according to any one of claims 1 to 11, wherein said prevention or treatment is characterized by a reduction of inflammation and / or oxidative stress in hair follicles.

13. (Multi-Multi) 13. The oral dosage unit for use, method or use according to any one of claims 1 to 12, wherein a daily dose equivalent to about 14 mg to about 21 mg of estetrol, preferably about 14 mg to about 16 mg or about 19 mg to about 21 mg of estetrol, is administered.

14. (Multi-Multi) 14. The oral dosage unit for use, method or use according to any one of claims 1 to 13, wherein the estetrol component is estetrol or an ester thereof, preferably the estetrol component is estetrol monohydrate.

15. (Multi-Multi) 15. The oral dosage unit, method or use according to any one of claims 1 to 14, wherein the dosage unit does not contain a progestogen or no progestogen is used or co-administered.

16. (Multi-Multi) 15. The oral dosage unit for use, method or use according to any one of claims 1 to 14, wherein a progestogen is present in the oral dosage unit or a progestogen is used, co-administered or administered after treatment with estetrol, preferably the progestogen is selected from the group comprising progesterone, drospirenone, norethisterone, norethisterone-acetate (NETA), norethindrone, dydrogesterone, levonorgestrel (LNG), etonogestrel, norgestrel, nomegestrol, nomegestrol-acetate (NOMAC), trimegestone, nestorone, dydrogesterone, gestodene, desogestrel, norgestimate, cyproterone acetate, dienogest and chlormadinone, more preferably the progestogen is selected from the group comprising drospirenone, progesterone or dydrogesterone.

17. 17. An oral dosage unit or method for use according to claim 16, wherein the progestogen is present in or used or co-administered or administered in the oral dosage unit in an amount equivalent to about 1 mg to about 4 mg, more preferably about 0.25 mg to about 4 mg, such as about 1 mg to about 3 mg, about 2.5 mg to 3.5 mg of drospirenone, or the progestogen is administered in an amount equivalent to about 2.5 mg to 3.5 mg of drospirenone.

18. (Multi-Multi) 18. An oral dosage unit for use, use or method according to any one of claims 1 to 17, wherein a further active ingredient suitable for the prevention or treatment of hair loss is present in said oral dosage unit or a further active ingredient suitable for the prevention or treatment of hair loss is co-administered or administered before or after treatment with estetrol.

19. (Multi-Multi) 19. An oral dosage unit or method for use according to any one of claims 1 to 18, wherein the composition is formulated as an oral dosage unit, preferably wherein the composition is formulated for oral, sublingual, buccal or labial administration.

20. (Multi-Multi) 20. The oral dosage unit or method for use according to any one of claims 1 to 19, wherein said oral dosage unit is formulated to correspond to a daily dosage unit or is administered as a daily dosage unit, respectively.

Citation Information

Patent Citations

  • A method of treating human skin and a skin care composition for use in such a method

    WO2003103685A1